<?xml version="1.0" encoding="UTF-8"?>
<Bundle xmlns="http://hl7.org/fhir">
  <id value="bundle-paxlovidfctablets"/>
  <meta>
    <versionId value="1"/>
    <lastUpdated value="2024-01-31T00:00:00Z"/>
    <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
  </meta>
  <language value="zh"/>
  <identifier>
    <system value="https://mcp.fda.gov.tw/"/>
    <value value="paxlovid"/>
  </identifier>
  <type value="document"/>
  <timestamp value="2024-01-31T00:00:00Z"/>
  <entry>
    <fullUrl value="urn:uuid:97739d08-3a4f-4739-9433-2ae56f522dfc"/>
    <resource>
      <Composition>
        <id value="97739d08-3a4f-4739-9433-2ae56f522dfc"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
        </meta>
        <language value="zh"/>
        <contained>				
            <Binary>
                <id value="nirmatrelvir"/>
                <contentType value="image/jpeg"/>
                <data value="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"/>
            </Binary>
        </contained>
        <contained>				
            <Binary>
                <id value="ritonavir"/>
                <contentType value="image/jpeg"/>
                <data value="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"/>
            </Binary>
        </contained>
        <contained>				
            <Binary>
                <id value="category"/>
                <contentType value="image/jpeg"/>
                <data value="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"/>
            </Binary>
        </contained>
        <extension url="http://hl7.org/fhir">
            <valueReference>
                <reference value="#nirmatrelvir"/>
            </valueReference>
        </extension>
        <extension url="http://hl7.org/fhir">
            <valueReference>
                <reference value="#ritonavir"/>
            </valueReference>
        </extension>
        <extension url="http://hl7.org/fhir">
            <valueReference>
                <reference value="#category"/>
            </valueReference>
        </extension>
        <version value="1"/>
				<date value="2024-01-31T00:00:00Z"/>
				<status value="final"/>
        <identifier>
          <system value="https://mcp.fda.gov.tw/"/>
          <value value="97739d08-3a4f-4739-9433-2ae56f522dfc"/>
        </identifier>
        <type>
          <coding>
            <system value="2.16.840.1.113883.6.1"/>
            <code value="34391-3"/>
            <display value="HUMAN PRESCRIPTION DRUG LABEL"/>
          </coding>
        </type>
        <subject>
          <reference value="urn:uuid:cfaeff60-72ff-42e0-bf17-d56db0f2da16"/>
        </subject>
        <author>
          <reference value="urn:uuid:e7fec37a-af43-4b91-9ec3-e7b2c5cb869b"/>
        </author>
        <title value="Paxlovid Human Prescription Drug Label"/>        
      <section>
        <title value=""/>
        <code>
          <coding>
            <system value="2.16.840.1.113883.6.1"/>
            <code value=""/>
            <display value=""/>
          </coding>
        </code>
        <text>
          <status value="generated"/>
          <div xmlns="http://www.w3.org/1999/xhtml">
            <p style="text-align: center">倍拉維150毫克/100毫克膜衣錠</p>
            <p style="text-align: center">PAXLOVID 150mg/100mg film-coated tablets</p>
            <p style="text-align: right">衛部藥輸字 第 028474 號</p>
            <p style="text-align: right">須由醫師處方使用</p>
            <p style="text-align: right">版本日期 2024-02-</p>
            <table>
                <tr>
                    <td>
                        <p style="text-align: center">特殊警語：PAXLOVID 的重要藥物交互作用</p>
                        <p>PAXLOVID包括ritonavir，此為一種強效
                        CYP3A 抑制劑，可能導致某些併用藥物的血中暴露量顯</p>
                        <p>著增加，進而造成潛在嚴重、危及生命或致命事件 [參見禁忌
                        (4)、警語/注意事項 (5.1)，以及交互</p>
                        <p>作用 (7)]。</p>
                        <p>開立 PAXLOVID 處方前：1) 檢查病人服用的所有藥物，以評估與類似 PAXLOVID 的強效</p>
                        <p>CYP3A 抑制劑之間潛在的藥物交互作用，並且 2) 確認併用藥物是否需要調整劑量、中斷劑量和/或</p>
                        <p>進行額外監測 [參見交互作用 (7)]。</p>
                        <p>考量 PAXLOVID 治療在減少住院和死亡方面的益處，以及每個病人的潛在藥物交互作用風險是否</p>
                        <p>可以適當處置 [參見警語/注意事項(5.1)、交互作用(7)和臨床試驗資料(12)]。</p>
                    </td>
                </tr>
            </table>
          </div>
        </text>
        <section>
          <title value="1 性狀"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p>PAXLOVID  為 nirmatrelvir 錠劑與ritonavir錠劑組合包裝。Nirmatrelvir是一種 SARS-CoV-2 主要蛋 白酶 (M<sup>pro</sup>) 抑制劑，ritonavir是一種 HIV-1 蛋白酶抑制劑和 CYP3A 抑制劑。</p>
                <p><i>Nirmatrelvir</i></p>
                <p>Nirmatrelvir活性成分的化學名稱為：(1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-</p>
                <p>azabicyclo[3.1.0]hexane-2-carboxamide]。其分子式為 C<sub>23</sub>H<sub>32</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub>，分子量為 499.54。</p>
                <p>Nirmatrelvir 的結構式為：</p>
                <p><img src="#nirmatrelvir" alt="nirmatrelvir chemical structure"/></p>
                <p><i>Ritonavir</i></p>
                <p>Ritonavir的化學名為 10-Hydroxy-2-methyl-5-(1-methylethyl)-1- [2-(1 methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12- tetraazatridecan-13-oic acid, 5-thiazolylmethylester, [5S-(5R*,8R*,10R*,11R*)]。Ritonavir的分子式為 C<sub>37</sub>H<sub>48</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub>，分子量為 720.95。</p>
                <p>Ritonavir的結構式為：</p>
                <p><img src="#ritonavir" alt="ritonavir chemical structure"/></p>
            </div>
          </text>
          <section>
            <title value="1.1 有效成分及含量"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">                
                <p><i>Nirmatrelvir</i></p>
                <p>每錠含 150 mg nirmatrelvir。</p>
                <p><i>Ritonavir</i></p>
                <p>每錠含有 100 mg ritonavir。</p>
              </div>
            </text>
          </section> 
          <section>
            <title value="1.2 賦形劑"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p><i>Nirmatrelvir</i></p>
                <p>非活性成分如下：colloidal silicon dioxide、croscarmellose sodium、lactose monohydrate、microcrystalline cellulose 和 sodium stearyl fumarate。膜衣的成分如下：hydroxy propyl methylcellulose、iron oxide red、polyethylene glycol 和 titanium dioxide。</p>
                <p>已知作用賦形劑：</p>
                <p>每錠粉紅色150 mg膜衣錠含有176 mg乳糖。</p>
                <p><i>Ritonavir</i></p>
                <p>其非活性成分如下： copovidone、sorbitan laurate、silica colloidal anhydrous、calcium hydrogen phosphate anhydrous和 sodium stearyl fumarate。膜衣的成分如下：hypromellose、titanium dioxide、macrogol、hydroxypropyl cellulose、talc、silica colloidal anhydrous和 polysorbate 80。</p>
              </div>
            </text>
          </section> 
          <section>
            <title value="1.3 劑型"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>PAXLOVID 為 nirmatrelvir 錠劑與ritonavir錠劑組合包裝。</p>
                <p>Nirmatrelvir為膜衣錠。</p>
                <p>Ritonavir為膜衣錠。</p>
              </div>
            </text>
          </section> 
        <section>
          <title value="1.4 藥品外觀"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">              
              <ul>
                <li><p>Nirmatrelvir 膜衣錠</p></li>
              </ul>                
              <p>粉紅色，橢圓型，一側刻有“PFE”字樣，另一側刻有“3CL”字樣。</p>
              <ul>
                <li><p>Ritonavir膜衣錠</p></li>
              </ul>              
              <p>白色至灰白色，膠囊狀錠劑，一側刻有“H” 字樣，另一側刻有“R9” 字樣。</p>
            </div>
          </text>
        </section> 
        </section> 
        <section>
          <title value="2 適應症"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">              
              <p>適用於治療 12 歲以上、具有進展為重症風險因子之輕度至中度新型冠狀病毒疾病(COVID-19) 病人。</p>
              <p>使用的限制</p>
              <ul>
                <li>
                    <p>PAXLOVID 尚未被核准用於 COVID-19 的暴露前或暴露後的預防治療。</p>
                </li>
                <li>
                    <p>PAXLOVID 未被核准連續使用超過 5  天。</p>
                </li>
              </ul>
            </div>
          </text>
        </section> 
        <section>
          <title value="3 用法及用量"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml"/>
          </text>
          <section>
            <title value="3.1 用法用量"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>建議劑量</p>                
                <p>PAXLOVID 的建議劑量為 300 mg nirmatrelvir（2 顆 150 mg 錠劑）和 100 mg ritonavir（1 顆 100 mg 錠劑）的錠劑組合包裝，3 顆錠劑一同服用，每日兩次，持續 5 天。應在診斷為 COVID 19  後以及症狀發作後 5 天內儘快開始 PAXLOVID 的 5 天療程，即使基準期的COVID-19症狀輕 微。青少年病人體重須達40公斤以上，方可使用。</p>
                <p>未能正確地3顆錠劑併用可能導致血漿中的 nirmatrelvir 濃度不足以達到預期的治療效果。根據公 共衛生建議，完成完整的 5 天療程和持續隔離對最大限度地清除病毒和最大限度地減少 SARS-CoV-2 的傳播非常重要。</p>               
                <p>因重症或危急 COVID-19 而需要住院治療的病人，在開始 PAXLOVID 治療後，病人應根據醫療保 健專業人員的評估完成完整的 5天治療療程。</p>
                <p>如果病人在預計服藥的 8 小時內漏服一劑 PAXLOVID，病人應儘快服藥並恢復正常的給藥時程。如果病人漏服一劑藥物的時間超過 8 小時，則不應服用漏服的劑量，而應按照常規用藥時間服用 下一劑藥物。病人不應因補足漏服的劑量而服用雙倍劑量的藥物。</p>
                <p>PAXLOVID（nirmatrelvir 和ritonavir錠劑）可與食物併服或不併服 [參見藥物動力學特性 (11)]。錠劑需整顆吞服，不得咀嚼、分開或壓碎。</p>
              </div>
            </text>
          </section> 
        <section>
          <title value="3.3 特殊族群用法用量"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml"/>
          </text>
          <section>
            <title value="3.3.1腎功能不全病人的重要用藥資訊"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>輕度腎功能不全（eGFR ≥ 60 至 &lt; 90 mL/min）病人建議無需調整劑量。</p>
                <p>在中度腎功能不全（eGFR ≥ 30 至 &lt; 60 mL/min）病人中，PAXLOVID 的劑量為 150 mg nirmatrelvir（一顆150 mg錠劑）和 100 mg ritonavir（一顆100 mg錠劑），兩種錠劑併用，每 日兩次，持續 5 天 [請見包裝及儲存 (13)] 。處方應詳細說明 PAXLOVID 內每種活性成分的劑量。</p>
                <p>在獲得更多資料之前，不建議重度腎功能不全 (eGFR &lt; 30 mL/min) 病人使用本品；尚未確定重 度腎功能不全病人的建議劑量 [參見特殊族群注意事項 (6.7) 和藥物動力學特性 (11)]。</p>
              </div>
            </text>
        </section>
            <section>
              <title value="3.3.2肝功能不全病人用藥"/>
              <code>
                <coding>
                  <system value="2.16.840.1.113883.6.1"/>
                  <code value=""/>
                  <display value=""/>
                </coding>
              </code>
              <text>
                <status value="generated"/>
                <div xmlns="http://www.w3.org/1999/xhtml">
                  <p>對於輕度（Child Pugh A 級）或中度（Child Pugh B 級）肝功能不全病人無需調整劑量。</p>
                  <p>尚無關於重度肝功能不全（Child-Pugh C 級）受試者使用 nirmatrelvir 或ritonavir的藥物動力學 或安全性資料；因此，不建議重度肝功能不全病人使用 PAXLOVID [參見特殊族群注意事項(6.6)]。</p>                     
                </div>
              </text>
            </section> 
        </section>
        <section>
          <title value="4 禁忌"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
                <p>對活性成分（nirmatrelvir 或ritonavir）或產品的任何其他成分有臨床顯著過敏反應史 [例如毒性表皮 溶解症 (TEN) 或 Stevens-Johnson 綜合症] 的病人禁用本品。</p>                  
                
                <p>禁止PAXLOVID與以下藥物併用，包括主要由 CYP3A 代謝且濃度升高與嚴重和/或危及生命反應相關 之藥物，以及顯著降低nirmatrelvir 或 ritonavir血漿濃度，可能與失去病毒學反應和抗藥性相關的強 效 CYP3A 誘導劑藥物。還有部分其他藥物與 PAXLOVID 併用應避免，和/或建議調整劑量、中斷劑 量或進行治療監測。本章節中列出的藥物為指引，並非所有可能與PAXLOVID 禁止併用藥物的完整列 表。醫療照護提供者應查閱其他其他適當的資源，如交互作用藥物的仿單，以獲得關於併用強效 CYP3A 抑制劑（如PAXLOVID）的給藥或監測之全面的資訊[參見交互作用 (7.3)]：</p>
                <p>主要由 CYP3A 代謝，並且其濃度升高與嚴重和/或危及生命反應相關之藥物 [參見交互作用 (7.3)]包括</p>
                <p>：</p>
                <ul>
                    <li><p>α1 - 腎上腺素能受體拮抗劑：alfuzosin</p></li>
                    <li><p>抗心絞痛藥：ranolazine</p></li>
                    <li><p>-抗心律不整藥：amiodarone、dronedarone、flecainide、propafenone、quinidine</p></li>
                    <li><p>抗痛風藥：colchicine（針對腎和/或肝功能不全的病人 [參見表 1、交互作用(7.3)]）</p></li>
                    <li><p>抗精神病藥：lurasidone、pimozide</p></li>
                    <li><p>良性攝護腺肥大藥物：silodosin</p></li>
                    <li><p>心血管藥物：eplerenone、ivabradine</p></li>
                    <li><p>麥角衍生物：dihydroergotamine、ergotamine、methylergonovine</p></li>
                    <li><p>HMG-CoA 還原酶抑制劑：lovastatin、simvastatin（可以暫時停用這些藥物，以允許使用 PAXLOVID [參見表 1、交互作用 (7.3)]）</p></li>
                    <li><p>免疫抑制劑：voclosporin</p></li>
                    <li><p>微體三酸甘油酯傳送蛋白抑制劑：lomitapide</p></li>
                    <li><p>偏頭痛藥：eletriptan、ubrogepant</p></li>
                    <li><p>礦物性皮質激素受體拮抗劑：finerenone</p></li>
                    <li><p>類鴉片拮抗劑：naloxegol</p></li>
                    <li><p>PDE5 抑制劑：sildenafil (Revatio®) 用於治療肺動脈高壓 (pulmonary arterial hypertension，PAH)</p></li>
                    <li><p>鎮定/安眠藥：triazolam、oral midazolam</p></li>
                    <li><p>血清素受體 1A致效劑/血清素受體 2A 拮抗劑：flibanserin</p></li>
                    <li><p>血管加壓素受體拮抗劑：tolvaptan</p></li>
                </ul>
                <p>顯著降低 nirmatrelvir 或ritonavir血中濃度的強效 CYP3A 誘導劑可能與潛在的抗病毒活性喪失和可 能的抗藥性相關。由於停用CYP3A 誘導劑的延遲補償反應，停用以下任何藥物後無法立即開始 PAXLOVID 治療 [參見交互作用 (7.3)]：</p>  
                <ul>
                    <li><p>抗癌藥物：apalutamide</p></li>
                    <li><p>抗痙攣藥：carbamazepine、phenobarbital、primidone、phenytoin </p></li>
                    <li><p>囊腫纖維化跨膜傳導調節蛋白增效劑：lumacaftor/ivacaftor</p></li>
                    <li><p>抗分枝桿菌藥物：rifampin、rifapentine</p></li>
                    <li><p>草藥：聖約翰草（St. John’s Wort (hypericum perforatum)）</p></li>
                </ul>
            </div>
          </text>
        </section>              
          </section> 
        </section> 
        <section>
            <section>
                <title value="5 警語及注意事項"/>
                <code>
                  <coding>
                    <system value="2.16.840.1.113883.6.1"/>
                    <code value=""/>
                    <display value=""/>
                  </coding>
                </code>
                <text>
                  <status value="generated"/>
                  <div xmlns="http://www.w3.org/1999/xhtml"/>
                </text>
                <section>
          <title value="5.1 警語/注意事項"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml"/>
          </text>
          <section>
            <title value="5.1.1藥物交互作用導致的嚴重不良反應風險"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>在接受經 CYP3A 代謝的藥物的病人中開始使用 PAXLOVID（含 ritonavir，一種強效 CYP3A 抑 制劑），或在已經接受 PAXLOVID 的病人中開始使用經 CYP3A 代謝的藥物可能會增加該 CYP3A 代謝的藥物的血漿濃度。</p>
                <p>誘導 CYP3A 的藥物可能會降低 PAXLOVID 的濃度。</p>
                <p>這些交互作用可能導致：</p>
                <ul>
                    <li><p>有臨床意義的不良反應，由於伴隨用藥的暴露量更高，可能導致重度、危及生命或致死性事 件。</p></li>
                    <li><p>PAXLOVID 的治療作用喪失和可能的病毒抗藥性。</p></li>
                </ul>
                
                
                <p>接受 PAXLOVID 治療的病人中曾報告因藥物交互作用發生嚴重、危及生命和/或致命的不良反應 。最常報告造成嚴重不良反應的併用藥物為鈣調磷酸酶抑制劑[例如，tacrolimus、cyclosporine (環孢菌素)]，其次是鈣通道阻斷劑。</p>
                <p>開立 PAXLOVID 處方前，檢視病人服用的所有藥物，以評估潛在的藥物交互作用，並確定併用藥 物是否需要調整劑量、中斷劑量和/或進行額外監測（例如鈣調磷酸酶抑制劑）[參見禁忌 (4) 和交 互作用 (7)]。具有臨床意義的藥物交互作用見表 1，包括禁忌藥物。表1 中列出的藥物為指引，並 非所有可能與PAXLOVID 交互作用藥物的完整列表。</p>
                <p>考量 PAXLOVID 治療在減少住院和死亡方面的益處，以及每個病人的潛在藥物交互作用風險是否 可以適當處置 [參見交互作用 (7)和臨床試驗資料 (12)]。</p>
              </div>
            </text>
        </section>
            <section>
              <title value="5.1.2過敏反應"/>
              <code>
                <coding>
                  <system value="2.16.840.1.113883.6.1"/>
                  <code value=""/>
                  <display value=""/>
                </coding>
              </code>
              <text>
                <status value="generated"/>
                <div xmlns="http://www.w3.org/1999/xhtml">
                  <p>曾通報使用 PAXLOVID 發生過敏性反應、嚴重皮膚反應（包括毒性表皮溶解症 [TEN] 及Stevens-Johnson 綜合症），以及其他過敏反應 [參見副作用/不良反應(8.1)]。如果發生臨床顯著過敏反應 或嚴重過敏性反應的徵兆和症狀，立即停用 PAXLOVID 及開始採取適當用藥和/或支持照護。</p>
                </div>
              </text>
            </section>
              <section>
                <title value="5.1.3肝臟毒性"/>
                <code>
                  <coding>
                    <system value="2.16.840.1.113883.6.1"/>
                    <code value=""/>
                    <display value=""/>
                  </coding>
                </code>
                <text>
                  <status value="generated"/>
                  <div xmlns="http://www.w3.org/1999/xhtml">
                    <p>接受 ritonavir 的病人曾出現肝轉氨酶升高、臨床肝炎和黃疸。因此，對既存肝病、肝酶異常或肝 炎病人進行 PAXLOVID 給藥時應謹慎。</p>
                  </div>
                </text>
                <section>
                  <title value="5.1.4產生人類免疫缺陷病毒 1 (HIV-1) 抗藥性的風險"/>
                  <code>
                    <coding>
                      <system value="2.16.840.1.113883.6.1"/>
                      <code value=""/>
                      <display value=""/>
                    </coding>
                  </code>
                  <text>
                    <status value="generated"/>
                    <div xmlns="http://www.w3.org/1999/xhtml">
                      <p>由於 nirmatrelvir 與ritonavir合併給藥，在未控制或未確診 HIV-1 感染的個體中可能存在對 HIV 蛋白酶抑制劑產生抗藥性的風險 [參見禁忌 (4) 和交互作用 (7)]。</p>
                    </div>
                  </text>
                </section> 
              </section> 
            </section> 
          </section>         
        <section>
          <title value="6 特殊族群注意事項"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml"/>
          </text>
          <section>
            <title value="6.1 懷孕"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p><i>風險總結</i></p>
                <p>目前有關妊娠期間使用 nirmatrelvir 的可用資料不足以評估主要出生缺陷、流產或母體或胎兒不 良的藥物相關風險。已發表的關於孕婦使用ritonavir的觀察性研究未發現重大出生缺陷的風險增 加。已發表的ritonavir研究不足以確定藥物相關的流產風險（參見資料）。妊娠期間如不予治療，COVID-19 會對母嬰構成風險（參見臨床注意事項）。</p>
                <p>在 nirmatrelvir 的動物胚胎-胎兒發育研究中，妊娠母兔口服給予nirmatrelvir，在全身暴露量 (AUC) 約為PAXLOVID 的核准人體劑量臨床暴露量的 11 倍時，觀察到胎兒體重減輕。在 nirmatrelvir 的動物生殖研究中，在全身暴露量 (AUC) 為 PAXLOVID 的核准人體劑量臨床暴露量 的 3 倍或 3 倍以上時，未觀察到其他不良發育結果（參見資料）。</p>
                <p>在ritonavir的胚胎-胎兒發育研究中，妊娠大鼠和母兔口服給予ritonavir，全身暴露量 (AUC) 為 PAXLOVID 的核准人體劑量臨床暴露量的 5倍 (大鼠) 或8 倍 (母兔) 以上時，未觀察到不良發育結 果的證據（參見資料）。 </p>
                <p>在適用人群中，主要出生缺陷和流產的估計背景風險不明。所有妊娠均面臨出生缺陷、流產或其 他不良結果的風險。在美國一般人群中，臨床確認的妊娠中主要出生缺陷和流產的估計背景風險 分別為 2 - 4% 和 15 - 20%。</p>
                <p><i>臨床注意事項</i></p>
                <p>疾病相關母體和/或胚胎/胎兒風險</p>
                <p>妊娠中的 COVID-19 與母體和胎兒的不良反應有關，包括子癲前症、子癲、早產、早期破水、靜 脈血栓疾病和胎兒死亡。</p>
                <p><i>資料</i></p>
                <p>人體資料</p>
                <p><i>Ritonavir</i></p>
                <p>基於抗反轉錄病毒妊娠登記的暴露於含ritonavir療程後活產的前瞻性報告（包括3,500 多例在妊 娠早期暴露的活產嬰兒和 3,500 多例在妊娠中期和晚期暴露的活產嬰兒），在亞特蘭大先天性缺 陷專案 (MACDP) 的參考人群中，暴露於ritonavir後總體出生缺陷率與美國參考人群 2.7% 的背景</p>
                <p>出生缺陷率相比無差異。妊娠早期暴露於含ritonavir治療療程後，活產嬰兒出生缺陷的患病率為 2.4% [95% 信賴區間 (CI)：1.9%，2.9%]，妊娠中期和晚期暴露於含ritonavir治療療程後，出生 缺陷的患病率為 2.9%（95% CI：2.4%，3.5%）。雖然ritonavir的胎盤轉移和胎兒體內檢測到的 ritonavir濃度通常較低，但在臍帶血樣本和新生兒毛髮中觀察到了可檢出。</p>
                <p>動物資料</p>
                <p><i>Nirmatrelvir</i></p>
                <p>在妊娠大鼠和兔子口服給予達 1000 mg/kg/天 nirmatrelvir 的劑量下，在器官形成期間 [大鼠妊 娠後第6 - 17 天和兔子妊娠後第 7 - 19 天]，進行胚胎-胎兒發育毒性研究。在大鼠胚胎-胎兒發育  研究中未發現具生物學意義的發育反應。在最高劑量 1000 mg/kg/天時，nirmatrelvir在大鼠的 全身暴露量 (AUC 24 ) ， 約為PAXLOVID 的核准人體劑量臨床暴露量的 9 倍。在兔子 胚胎-胎兒發 育 研究中，在 1000 mg/kg/天劑量下觀察到胎兒體重降低（降低 9%），但無顯著母體毒性結果 。在 1000 mg/kg/天的劑量下，兔子的全身暴露量(AUC 24 ) 約為 PAXLOVID 的核准人體劑量臨 床暴露量的 11 倍。達最高試驗劑量 1000 mg/kg/天時，未觀察到其他顯著的發育毒性（畸形和 胚胎-胎兒致死）。劑量為 300 mg/kg/天時未觀察到兔子的發育反應，該劑量的全身暴露量 (AUC 24 ) 約為PAXLOVID 的核准人體劑量臨床暴露量的3 倍。一項在妊娠大鼠第 6 天至哺乳期第 20 天 (LD) 口服達 1000 mg/kg/天 nirmatrelvir的產前和產後發育 (PPND) 試驗中，顯示沒有不 良發現。儘管比較 nirmatrelvir 治療組與對照組動物出生的子代時，於出生時未觀察到體重差異 且不存在母體毒性，但於出生後 (PND) 第 17 天（下降 8%）和 PND 第 21 天（下降最多達 7%）觀察到子代體重下降。出生後第28 天至 第 56天，未觀察到子代體重存在顯著差異。 mg/kg/天劑量下的母體全身暴露量 (AUC 24) 約為PAXLOVID 的核准人體劑量臨床暴露量的 9 倍 。在 300 mg/kg/天劑量下未觀察到子代體重變化，該劑量下全身母體暴露量(AUC 24 ) 約為 PAXLOVID 的核准人體劑量臨床暴露量的 6 倍。</p>
                <p><i>Ritonavir</i></p>
                <p>在器官形成期間，於妊娠後第6 - 17 天口服給予妊娠大鼠（0、15、35 和 75 mg/kg/天）和於妊 娠後第 6 - 19 天給予妊娠兔子（0、25、50 和 110 mg/kg/天）ritonavir。全身暴露量 (AUC)約 為 PAXLOVID核准人體劑量暴露量的 5 倍 (大鼠) 或8倍(兔子) 時，在大鼠和兔子中未觀察到 ritonavir引起致畸性的證據。存在母體毒性時，大鼠全身暴露量 (AUC) 約為 PAXLOVID 的核准人 體劑量暴露量的10倍，觀察到早期再吸收、骨化延遲和發育異常的發生率增加，以及胎兒體重下 降。兔子產生母體毒性，其劑量全身暴露量 (AUC) 約為PAXLOVID 的核准人體劑量暴露量的8倍 ，觀察到再吸收、窩仔數減少和胎兒體重下降。在一項大鼠的產前產後發育研究(pre and postnatal development，PPND)中，從 妊娠後第 6 天到出生後第 20 天給予 0、15、35 和 60 mg/kg/天的ritonavir，在全身暴露量 (AUC) 為PAXLOVID 的核准人體劑量暴露量的的10倍時，不會造成發育毒性。</p>
              </div>
            </text>
          </section> 
        <section>
          <title value="6.2 哺乳"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p><i>風險總結</i></p>
              <p>關於 nirmatrelvir 是否可分泌至人或動物乳汁、對母乳餵養嬰兒的影響或對乳汁分泌的影響，目 前尚無可取得的資料。在給予 nirmatrelvir 的大鼠的哺乳後代中觀察到體重暫時性下降（參見資 料）。有限的已發表資料顯示，ritonavir出現於乳汁中。尚無關於 ritonavir 對母乳餵養嬰兒產生 的影響或藥物對泌乳量產生的影響之資料。應考慮母乳餵養的發育和健康益處，以及母親對 PAXLOVID 的臨床需求以及 PAXLOVID 或母體基礎狀況對母乳餵養嬰兒的任何潛在不良影響。感 染 COVID‑19 的哺乳期女性應遵循臨床指引的規定，以避免使嬰兒暴露於 COVID‑19。</p>
              <p><i>資料</i></p>
              <p>在 PPND 試驗中，給予妊娠大鼠 nirmatrelvir 劑量的全身暴露量 (AUC 24) 約為 PAXLOVID 核准 人體劑量臨床暴露量的 9 倍時，在子代觀察到短暫的體重下降（最高達 8%）。在母體全身暴露 量 (AUC 24 ) 約為 PAXLOVID 的核准人體劑量臨床暴露量的 6 倍時，未觀察到子代的體重變化。</p>
            </div>
          </text>
        </section> 
        <section>
          <title value="6.3 有生育能力的女性與男性"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p>避孕</p>              
              <p>Ritonavir 的使用可能會降低複合荷爾蒙避孕藥的有效性。建議使用複合荷爾蒙避孕藥的病人使用 有效的替代避孕方法或額外的屏障避孕方法 [參見交互作用 (7.3)]。</p>
            </div>
          </text>
        </section> 
        <section>
          <title value="6.4 小兒"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p>PAXLOVID 未核准用於小於12 歲或體重 &lt; 40 kg 的兒童病人。PAXLOVID 在兒童病人中的安全 性和有效性尚未確定。使用成人劑量在 ≥ 12 歲且體重至少為 40 kg 的病人中可導致 nirmatrelvir 和ritonavir的血清暴露量與在成人中觀察到的結果相當(因體重相似的成人亦被納入 試驗 EPIC-HR 中) [參見副作用/不良反應 (8.2)、藥物動力學特性 (11) 和臨床試驗資料 (12.1)]。</p>
            </div>
          </text>
        </section> 
        <section>
          <title value="6.5 老年人"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p>PAXLOVID 的臨床研究包括 ≥ 65 歲的受試者，其資料有助於安全性和有效性的總體評估 [參見副 作用/不良反應 (8.2) 和臨床試驗資料(12.1)]。在包含 EPIC-HR 和 EPIC-SR 的整合資料集中隨機分 配至接受 PAXLOVID 的受試者總人數 (N = 1,578) 中，約有165位( 10%) 為 65 歲及以上，和 39位(2%) 為 75 歲及以上。在這些受試者和年輕受試者之間未觀察到安全性的整體差異，其他報 告的臨床經驗也尚未確定老年和年輕病人間的安全性差異，但不能排除部分老年人較敏感。</p>
            </div>
          </text>
        </section> 
        <section>
          <title value="6.6 肝功能不全"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p>對於輕度（Child Pugh A 級）或中度（Child Pugh B 級）肝功能不全病人建議無需調整 PAXLOVID 劑量。尚無關於重度（Child-Pugh C 級）肝功能不全受試者使用 nirmatrelvir 或 ritonavir的藥物動力學或安全性資料；因此，不建議重度（Child-Pugh C 級）肝功能不全病人使 用 PAXLOVID [參見警語/注意事項 (5.1.3) 和藥物動力學特性(11)]。</p>
            </div>
          </text>
        </section> 
        <section>
          <title value="6.7 腎功能不全"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p>腎功能不全會增加
                nirmatrelvir 的暴露量，這可能會增加PAXLOVID不良反應的風險。</p>
                <p>輕度腎功能不全（eGFR ≥ 60 至 &lt; 90 mL/min）病人建議不需要調整劑量。降低中度腎功能不全（eGFR ≥ 30 至 &lt; 60 mL/min）病人的 PAXLOVID 劑量。獲得更多資料之前，不建議患有重度腎 功能不全的病人(eGFR &lt;30 mL/min)或患有末期腎病 (eGFR &lt;15 mL/min)且正在接受透析的病人 使用PAXLOVID。目前尚未確定重度腎功能不全病人的合適劑量 [參見特殊族群用法用量(3.3.1)和 藥物動力學特性(11)]。處方應詳細說明 PAXLOVID 內每種活性成分的劑量。醫師/藥師應就腎功 能不全病人的給藥說明提供建議。</p>                
            </div>
          </text>
        </section> 
    </section>
        <section>
          <title value="7 交互作用"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml"/>
          </text>
          <section>
            <title value="7.1倍拉維(PAXLOVID) 影響其他藥物的可能性"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">                
                <p>PAXLOVID（nirmatrelvir 與ritonavir組合包裝）是 CYP3A 的強效抑制劑、及CYP2D6、P-gp 和 OATP1B1的抑制劑。併用PAXLOVID和主要由 CYP3A以及CYP2D6代謝的藥物，或由P-gp 或 OATP1B1運輸的藥物，可能增加此類藥物的血漿濃度，並且增加不良事件的風險。禁止 PAXLOVID 與高度依賴於 CYP3A 清除且血漿濃度升高與嚴重和/或危及生命事件相關的藥物併用 [參見禁忌 (4) 和交互作用 (7.3)表 1]。與其他 CYP3A 受質藥物併用可能需要劑量調整或額外監測，如表1 所示。 </p>
              </div>
            </text>
          </section> 
          <section>
            <title value="7.2其他藥物影響倍拉維(PAXLOVID) 的可能性"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>Nirmatrelvir 和ritonavir是 CYP3A 受質；因此，誘導 CYP3A 的藥物可能會降低 nirmatrelvir 和 ritonavir的血漿濃度並降低 PAXLOVID 的治療效果 [參見禁忌 (4) 和交互作用 (7.3)表 1]。</p>
              </div>
            </text>
          </section> 
          <section>
            <title value="7.3已確定的和其他潛在重要的藥物交互作用"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>表 1 提供了一份有臨床意義的藥物交互作用列表，包括禁忌藥物 [參見禁忌 (4)和警語/注意事項 (5.1)]。表 1 中列出的藥物僅為指引，並非所有可能與 PAXLOVID 交互作用的藥物的完整列表。醫療 照護提供者應查閱其他適當的資源，如交互作用藥物的仿單，以獲得關於併用強效 CYP3A 抑制劑(如 ritonavir）的給藥或監測之全面的資訊。</p>
              </div>
            </text>
          </section>           
        </section> 
        <section>
          <title value="8 副作用/不良反應"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml"/>
          </text>
          <section>
            <title value="8.1 臨床重要副作用/不良反應"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>以下臨床重要不良反應於本仿單的其他章節進行說明：</p>    
                <ul>
                    <li><p>過敏反應 [參見警語及注意事項 (5.1.2)]</p></li>
                </ul>            
                
              </div>
            </text>
          </section> 
          <section>
            <title value="8.2 臨床試驗經驗"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>由於臨床試驗在多種不同條件下執行，藥品臨床試驗中觀察到的不良反應發生率，無法和另一種 藥品在臨床試驗中的發生率直接比較，且可能無法反應實務中的發生率。 PAXLOVID 的安全性係根據兩項試驗受試者為 18 歲及以上，且實驗室確診具有SARS-CoV-2感 染之有症狀成人受試者的第2/3期隨機分配、安慰劑對照試驗而定。兩項試驗中的受試者在症狀發 作後 5 天內每 12 小時接受一次 PAXLOVID（nirmatrelvir/ritonavir 300 mg/100 mg）或安慰劑，共 5 天，用於治療輕度至中度 COVID-19 [參見臨床試驗資料 (12) ]：</p>
                <ul>
                    <li><p>試驗C4671005 (EPIC-HR) 納入有進展為重症的高風險受試者。</p></li>
                    <li><p>試驗C4671002 (EPIC-SR) 納入有進展為重症的標準風險受試者（先前未接種疫苗，具有標</p></li>
                </ul>
                <p>準風險；或完整接種疫苗，具有至少1 個進展為重症之風險因子的受試者）。</p>
                <p>不良反應為受試者接受試驗藥物治療期間以及最後一劑試驗治療後 28 天內通報的不良事件。 試驗C4671005 (EPIC-HR)中有1,038名受試者接受了PAXLOVID，有1,053名受試者接受了安慰劑。最常見的不良反應（PAXLOVID 組的發生率 ≥ 1% 且發生頻率高於安慰劑組）為味覺障礙（分別為 5% 和 &lt;1%）以及腹瀉（分別為3% 和 2%）。 </p>
                <p>在試驗 C4671002 (EPIC-SR)，接種過疫苗或未接種疫苗且具有標準風險的受試者，或已完整接種疫苗且具有至少 1 項進展為重症之風險因子的受試者中，有540 名受試者接受 PAXLOVID 和 528 名受試者接受安慰劑。觀察到的不良反應與在 EPIC HR 中觀察到的一致。</p>
              </div>
            </text>
          </section> 
          <section>
            <title value="8.3 上市後經驗"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p><i>COVID-19 受試者的緊急使用授權經驗</i></p>
                <p>緊急使用授權下，PAXLOVID 於使用期間發現下列不良反應。</p>
                <p>免疫系統疾病：過敏性反應、過敏反應 [參見警語/注意事項(5.1.2)]</p>
                <p>皮膚和表皮組織疾病：毒性表皮溶解症、Stevens-Johnson 綜合症 [參見警語及注意事項(5.1.2)]</p>
                <p>神經系統疾病：頭痛</p>
                <p>血管疾病：高血壓</p>
                <p>胃腸疾病：腹痛、噁心、嘔吐</p>
                <p>全身性疾患及給藥部位狀況：不適</p>
              </div>
            </text>
          </section> 
        </section> 
        <section>
          <title value="9 過量"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p>PAXLOVID 藥物過量的治療 應包括一般支持性措施，包括監測生命徵象和觀察病人的臨床狀態。PAXLOVID 用藥過量沒有特效解毒劑。</p>
            </div>
          </text>
        </section> 
        <section>
          <title value="10 藥理特性"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value=""/>
              <display value=""/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml"/>
          </text>
          <section>
            <title value="10.1 作用機轉"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">                
                <p>Nirmatrelvir是一種嚴重急性呼吸道症候群冠狀病毒 2 型 (SARS-CoV-2) 抗病毒藥物[參見微生 物學 (11.1)]。</p>
                <p>Ritonavir是一種 HIV-1 蛋白酶抑制劑，但對 SARS-CoV-2 M<sup>pro</sup> 無活性。Ritonavir抑制經由 CYP3A調節nirmatrelvir的代謝，使 nirmatrelvir 的血漿濃度增加。 </p>
              </div>
            </text>
          </section> 
          <section>
            <title value="10.2 藥效藥理特性"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p><i>心臟電生理學</i></p>
                <p>在建議劑量穩態峰值血漿濃度(Cmax)的 3 倍時，nirmatrelvir不會延⻑ QTc 間隔至達任何臨床 相關程度。</p>              
              </div>
            </text>
          </section> 
          <section>
            <title value="10.3 臨床前安全性資料"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value=""/>
                <display value=""/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml"/>
            </text>
            <section>
              <title value="10.3.1致癌、致突變、生育力損害"/>
              <code>
                <coding>
                  <system value="2.16.840.1.113883.6.1"/>
                  <code value=""/>
                  <display value=""/>
                </coding>
              </code>
              <text>
                <status value="generated"/>
                <div xmlns="http://www.w3.org/1999/xhtml">
<p><i>Nirmatrelvir</i></p>
<p>尚未進行 nirmatrelvir 的致癌性研究。</p>
<p>在一系列體外和體內試驗中，包括使用 S. typhimurium 和E. coli的 Ames 細菌回復突變試驗、使用人類淋巴母細胞 TK6 細胞的體外微核試驗以及大鼠體內微核試驗，nirmatrelvir 的致突變 或致染色體斷裂活性為陰性。</p>
<p>在一項生育力和早期胚胎發育試驗中，雄性和雌性大鼠從交配前 14 天開始直到整個交配期每日一次口服給予 60、200 或 1000 mg/kg/天劑量的 nirmatrelvir，雌性大鼠持續至 妊娠後第6天，雄性大鼠總共給藥 32 次。在高達 1000 mg/kg/天的劑量下，對生育力、生殖能力或早期胚 胎發育沒有影響，導致全身暴露量（AUC 24 ）約為 PAXLOVID 的核准人體劑量暴露量的 5 倍。</p>
<p><i>Ritonavir</i></p>
<p>已對小鼠和大鼠進行ritonavir的致癌性研究。在雄性小鼠中，劑量為 50、100 或 200 mg/kg/天時，肝臟中腺瘤以及合併腺瘤和惡性腫瘤的發生率呈劑量依賴性增加。根據 AUC 測 量結果，高劑量下的暴露量約為 PAXLOVID 的核准人體使用劑量下人體暴露量的 25 倍。達最 高試驗劑量下，未在雌性動物中觀察到致癌作用，其劑量造成全身暴露量（AUC 24 ）約為 PAXLOVID 的核准人體劑量下人體暴露量的 25 倍。在以 7、15 或 30 mg/kg/天的劑量給藥的 大鼠中，未見致癌作用。在該試驗中，高劑量下的暴露量約為 PAXLOVID 的核准人體劑量下人 體暴露量的 5倍。</p>
<p>在一系列體外和體內試驗中，包括使用 S. typhimurium 和E. coli的Ames細菌回復突變試驗、小鼠淋巴瘤試驗、小鼠微核試驗和人類淋巴細胞的染色體變異試驗，發現ritonavir的致突變性 或致染色體斷裂活性為陰性。</p>
<p>Ritonavir在大鼠的暴露量約為 PAXLOVID 的核准人體劑量人體暴露量的18 倍（雄性）和27 倍 雌性）時，未對其生育力產生影響。</p>
                </div>
              </text>
            </section> 
            <section>
              <title value="11 藥物動力學特性"/>
              <code>
                <coding>
                  <system value="2.16.840.1.113883.6.1"/>
                  <code value=""/>
                  <display value=""/>
                </coding>
              </code>
              <text>
                <status value="generated"/>
                <div xmlns="http://www.w3.org/1999/xhtml">                  
                  <p>Nirmatrelvir/ritonavir 的藥物動力學在健康受試者和輕度至中度 COVID-19 受試者中相似。</p>
                  <p>與 100 mg ritonavir併用時，在 250 mg 至 750 mg（核准建議劑量的 0.83 至 2.5 倍）單劑量範圍 和 75 mg 至 500 mg（核准建議劑量的 0.25 至 1.67 倍）多劑量範圍內，nirmatrelvir AUC 以低於 劑量比例的方式增加。給予nirmatrelvir核准建議劑量後第 2 天達到穩定態，平均累積率約為 2 倍。</p>
                  <p>Nirmatrelvir/ritonavir的藥物動力學特性如表 2 所示。</p>
                  <p>表 2： 健康受試者中 Nirmatrelvir 和 ritonavir的藥物動力學特性</p>
                  <!-- Table placeholder-->
                  
                  <p>縮寫：CL/F = 擬似清除率；hr = 小時；L/hr =  每小時公升數；T1/2 = 末端排除半衰期；Tmax= </p>
                  <p>達到 Cmax 的時間；Vz/F = 擬似分布體積</p>
                  <p>a.    代表健康受試者接受 300 mg nirmatrelvir（2 × 150 mg 錠劑）和 100 mg ritonavir錠劑單次</p>
                  <p>給藥後的數據。</p>
                  <p>b.    單次口服 nirmatrelvir 300 mg後，在進食後（高脂肪和高熱量飲食）或禁食條件下於-12 小</p>
                  <p>時、0 小時和 12 小時服用ritonavir 100 mg 加強劑。</p>
                  <p>c.   300 mg nirmatrelvir（口服懸浮劑）併用 100 mg ritonavir（錠劑），每日兩次，持續 3 天。</p>
                  <p>d.    紅血球與血漿比率。</p>
                  <p>e.    在第 0 小時 300 mg nirmatrelvir 口服懸浮劑施用後，在-12 小時、0 小時、12 小時和 24 小</p>
                  <p>時用 100 mg ritonavir增強，通過^19 F-NMR 分析測定。</p>
                  <p>f.    採用 600 mg^14 C-ritonavir口服溶液給藥後，通過^14 C 分析測定（核准ritonavir劑量的6</p>
                  <p>倍）。</p>                  
                  <p>EPIC-HR 中接受 PAXLOVID 治療的輕度至中度 COVID-19 成人受試者之第 5 天 nirmatrelvir 預估</p>
                  <p>暴露參數如表 3 所示。</p>                  
                  <p>表 3：在每天兩次給藥 300 mg/100 mg Nirmatrelvir/Ritonavir 後感染輕度至中度 COVID-19 之受試者的第 5 天預估 Nirmatrelvir 暴露參數 </p>
                  <!-- Table placeholder-->
                  
                  <p>縮寫：Cmax = 預估最大濃度；Cmin = 預估最小濃度 (Ctrough)。</p>
                  <p>a.    資料以幾何平均數（第 10 和第 90 百分位數）呈現。</p>
                  <p>b.    根據1,106 名具有事後 PK 參數的受試者。</p>
                  <p>c.    AUCtau = 每天兩次給藥的從時間 0 至 12 小時的預估血漿濃度-時間曲線下面積。</p>
                  <p>食物的影響</p>
                  <p>給予健康受試者高脂肪飲食(800-1000卡路里；50%脂肪)後未觀察到nirmatrelvir的藥物動力學具有 臨床顯著差異。</p>
                  <p><i>特殊族群</i></p>
                  <p>根據年齡（18 至 86 歲）、性別或種族/族裔分類，nirmatrelvir 的藥物動力學並無臨床顯著差異。</p>
                  <p>兒童病人</p>
                  <p>使用群體藥物動力學模型，預計給藥方案根據體重校正後，在 12 歲及以上且體重至少 40 kg 的病人 中產生的 nirmatrelvir 穩定態血漿暴露與在成人中觀察到的相當。</p>
                  <p><i>腎功能不全病人</i></p>
                  <p>腎功能不全病人單次口服nirmatrelvir 100 mg劑量（核准建議劑量的0.33倍）併用ritonavir 100 mg後，nirmatrelvir的藥物動力學資料列於表4中。與無腎功能不全的健康對照組相比，輕度腎功能 不全病人中 nirmatrelvir Cmax 和 AUC 分別高出 30% 和 24%，中度腎功能不全病人分別高出 38% 和 87%，重度腎功能不全病人分別高出 48% 和 204%。</p>
                  <p>表 4： 腎功能不全對 Nirmatrelvir/Ritonavir藥物動力學的影響</p>
                  <!-- Table placeholder-->
                                    
                  <p>縮寫：AUCinf = 從時間零外推至無限時間的血漿濃度-時間曲線下面積；Cmax = 最高觀察濃度；CV= 變異係數；SD = 標準差；T1/2 = 末端排除半衰期；Tmax = 達到 Cmax 的時間。 除了 Tmax 的中位數（範圍）和 T1/2 的算術平均值 ± SD 以外，所有其他數值均為幾何平均值（幾何 %CV）。</p>
                  <p>肝功能不全病人</p>
                  <p>與健康受試者相比，中度（Child-Pugh B級）肝功能不全病人單次口服 nirmatrelvir 100 mg劑量（核准建議劑量的 0.33倍）併用100 mg ritonavir 後，nirmatrelvir 的藥物動力學相似。尚未研究重 度肝功能不全（Child-Pugh C 級）對 nirmatrelvir 或
                  ritonavir 藥物動力學的影響。</p>
                  <p><i>臨床藥物交互作用研究</i></p>
                  <p>表 5 說明了其他藥物對nirmatrelvir Cmax 和 AUC 的影響。</p>
                  
                  <p>表 5：其他藥物對Nirmatrelvir藥物動力學的影響</p>
                  <!-- Table placeholder-->
                                    
                  <p>縮寫：AUC= 血漿濃度-時間曲線下面積；AUCinf =從時間零外推至無限時間的血漿濃度-時間曲</p>
                  <p>線下面積；AUCtau  = 從時間零到時間 tau(τ) 的血漿濃度-時間曲線下面積，即給藥間隔；CI = 信</p>
                  <p>賴區間；Cmax = 觀察到最高血漿濃度。</p>
                  <p>a.    對於Carbamazepine，AUC = AUCinf，對於Itraconazole，AUC = AUCtau。</p>
                  <p>b.    第 8 天至第 15 天，Carbamazepine滴定至 300 mg，每日兩次（例如，第 1 - 3 天 100 m</p>
                  <p>g，每日兩次，第 4 - 7 天 200 mg，每日兩次）。</p>                  
                  <p>表 6 說明了nirmatrelvir/ritonavir 對其他藥物 Cmax 和 AUC 的影響。</p>
                  
                  <p>表 6：Nirmatrelvir/Ritonavir對其他藥物的藥物動力學的影響</p>
                  <!-- Table placeholder-->
                  
                  <p>縮寫：AUC = 血漿濃度-時間曲線下面積；CI = 信賴區間；Cmax = 觀察到最高血漿濃度；P‑gp = p‑醣蛋白。</p>
                  <p>a.    對於midazolam 和dabigatran，AUC=AUCinf</p>
                  <p>b.   對於midazolam，檢定組= nirmatrelvir/ritonavir 加上 midazolam，對照組 = Midazolam。</p>                 
                  
                  <p>Midazolam是CYP3A的指標受質。對於dabigatran，檢定組 = nirmatrelvir/ritonavir加上dabigat ran，對照組 = Dabigatran。Dabigatran是P-gp的指標受質。</p>
                </div>
              </text>
              <section>
                <section>
                    <title value="11 體外研究"/>
                    <code>
                      <coding>
                        <system value="2.16.840.1.113883.6.1"/>
                        <code value=""/>
                        <display value=""/>
                      </coding>
                    </code>
                    <text>
                      <status value="generated"/>
                      <div xmlns="http://www.w3.org/1999/xhtml">
                        <p>細胞色素 P450 (CYP) 酵素：</p>
                        <ul>
                            <li><p>Nirmatrelvir 為CYP3A的可逆和時間依賴性抑制劑，但非CYP1A2、CYP2B6、CYP2C8、CYP2C9、CYP2C19或CYP2D6的抑制劑。Nirmatrelvir 為 CYP2B6、2C8、2C9和3A4的誘導 劑藥物，但在建議的治療劑量下誘導這些 CYP 酵素引起藥物動力學交互作用的風險很小。</p></li>
                            <li><p>Ritonavir 是一種CYP2D6 和 CYP3A的受質。Ritonavir 為 CYP1A2、CYP2C9、CYP2C19、CYP2B6和CYP3A的誘導劑藥物。</p></li>
                        </ul>
                        <p>運輸系統：Nirmatrelvir 為P-gp 和 OATP1B1 的抑制劑。Nirmatrelvir 為P-gp受質，但非BCRP、MATE1、MATE2K、NTCP、OAT1、OAT2、OAT3、OCT1、OCT2、PEPT1、OATP1B1、OATP1B3、OATP2B1或OATP4C1的受質。</p>
                    </div>
                    </text>
                    <section>
                <title value="11.1 微生物學"/>
                <code>
                  <coding>
                    <system value="2.16.840.1.113883.6.1"/>
                    <code value=""/>
                    <display value=""/>
                  </coding>
                </code>
                <text>
                  <status value="generated"/>
                  <div xmlns="http://www.w3.org/1999/xhtml">
                    <p><i>作用機制</i></p>                    
                    <p>Nirmatelvir 是一種 SARS-CoV-2 主要蛋白酶 (M<sup>pro</sup>) 的擬肽抑制劑，也稱為
                    3C-like蛋白酶 (3CLpro) 或非結構性蛋白 5 (nsp5) 蛋白酶。SARS-CoV-2 M<sup>pro</sup> 的抑制使其無法處理病毒多聚 蛋白 pp1a 和
                    pp1ab，進而避免病毒複製。在生物化學分析中，nimatrelvir抑制重組 SARS-CoV-2 M<sup>pro</sup> 的活性，Ki 值為 3.1 nM，IC 50  值為 19.2 nM。以X射線晶體繞射法測定，發現 nirmatrelvir可直接與 SARS-CoV-2 M<sup>pro</sup> 活性位點結合。</p>                    
                    
                    <p><i>抗病毒活性</i></p>
                    <p>抗病毒活性的細胞培養實驗</p>
                    
                    <p>Nirmatrelvir 在感染SARS-CoV-2（USA-WA1/2020 分離株）之已分化的正常人類支氣管上皮 (dNHBE) 細胞株中表現出抗病毒活性，藥物暴露 3 天後，EC<sub>50</sub> 和 EC 90 值分別為 62 nM (31 ng/mL) 和 181 nM (90 ng/mL)。</p>                    
                    
                    <p>Nirmatrelvir 對 Omicron 子變異株 BA.2、BA.2.12.1、BA.4、BA.4.6、BA.5、BF.7、BQ.1、BQ.1.11 和 XBB.1.5 的抗病毒活性，在存在 P-gp 抑制劑的情況下於 Vero E6-TMPRSS2 細胞 中進行評估。Nirmatrevir 對 Omicron 子變異株的中位數EC<sub>50</sub>數值為 83
                    nM（範圍：39-146 nM），反映出相對於 USA-WA1/2020 分離株的 EC<sub>50</sub>數值倍數變化 ≤1.5。</p>                    
                    
                    <p>此外，在 Vero E6 P-gp 基因剔除細胞中評估了nirmatrelvir對 SARS-CoV-2 Alpha、Beta、Gamma、Delta、Lambda、Mu 和 Omicron
                    BA.1 變異株的抗病毒活性。Nirmatrevir 的中位 數 EC<sub>50</sub>數值為 25 nM（範圍：16-141 nM）。Beta 變異株是經測試最不敏感的變異株，相對 於 USA WA1/2020，其EC<sub>50</sub>數值倍數變化為 3.7。其他變異株相對於 USA-WA1/2020 的 EC 50  數值倍數變化 ≤1.1。</p>
                    
                    <p>臨床抗病毒活性</p>
                    <p>在納入主要感染 SARS-CoV-2 Delta 變異株受試者的臨床試驗 EPIC-HR 中，PAXLOVID 治療 與至第 5 天止鼻咽檢體中病毒 RNA 脫落中位數濃度值大幅下降 0.83 log 10 copies/mL 有關（mITT1 分析集，所有在基準期時未接受或未預期接受 COVID-19 治療性單株抗體 (mAb) 治療 且症狀發作≤5 天的經治療受試者）；在 mITT2 分析集（所有經治療，症狀發作≤5 天的受試者）中觀察到類似的結果。在包含感染 SARS-CoV-2 Delta (79%) 或 Omicron (19%) 變異株受試 者的EPIC-SR 試驗中，PAXLOVID 治療與至第 5 天止，鼻咽檢體中病毒 RNA 脫落中位數濃度</p>
                    <p>值大幅下降 1.05 log 10 copies/mL 有關，此下降幅度與在感染 Delta 或 Omicron 變異株的受 試者中觀察到的相似。PAXLOVID 治療 5 天後病毒 RNA 濃度相較於安慰劑的下降程度，與在 EPIC-HR 中未接種疫苗之高風險受試者和在 EPIC-SR 中已接種疫苗之高風險受試者相似。</p>

                    <p><i>抗病毒抗藥性</i></p>
                    <p>細胞培養與生化測定法</p>
                    <p>已透過多種方法辨識出可能與 nirmatrelvir 抗藥性相關的SARS-CoV-2 M<sup>pro</sup>殘留物，包括 SARS-CoV-2 抗藥性選擇、檢測帶有 M<sup>pro</sup> 置換的重組 SARS-CoV-2 病毒，以及生化測定內含 基酸置換的重組 SARS-CoV-2 M<sup>pro</sup>。表 7 提供於nirmatrelvir 選擇性 SARS-CoV-2 細胞培 養內觀察到的 M<sup>pro</sup> 置換及 M<sup>pro</sup> 置換組合。列出所有個別
                    M<sup>pro</sup> 置換，無論為單獨出現或與其 他 M<sup>pro</sup> 置換組合出現。請注意，M<sup>pro</sup> S301P 和 T304I 置換會與位於 M<sup>pro</sup> C 末端 nsp5/nsp6 切割位點的 P6 和 P3 位置重疊。在細胞培養中，其他 M<sup>pro</sup> 切割位點的置換與 nirmatrelvir 抗藥性間無關聯性。這些置換的臨床意義尚不清楚。</p>

                    <p>表 7： 細胞培養中Nirmatrelvir選擇性SARS-CoV-2</p>
                    <!-- Table placeholder-->
                    
                    <p>縮寫：ND = 無資料。</p>
                    <p>在使用含有胺基酸置換的重組 SARS-CoV-2 M<sup>pro</sup> 的生化測定法中，以下 SARS-CoV-2 M<sup>pro</sup>置</p>
                    <p>換導致nirmatrelvir 活性降低 ≥3 倍（以Ki 值為基準的差異倍數）： Y54A (25)、F140A (21)、F140L (7.6)、F140S (260)、G143S (3.6)、S144A (46)、S144E (480)、S144T (170)、H164N (6.7)、E166A (35)、E166G (6.2)、E166V (7,700)、H172Y (250)、A173S (4.1)、A173V (16)、R188G (38)、Q192L (29)、Q192P (7.8)和V297A (3.0)。此外，以下M<sup>pro</sup>置換組合造成 nirmatrelvir 活性降低 ≥3 倍：T21I+S144A (20)、T21I+E166V (11,000)、T21I+A173V (15)、L50F+E166V (4,500)、T135I+T304I (5.1)、F140L+A173V
                    (95)、H172Y+P252L (180)、A173V+T304I (28)、T21I+S144A+T304I (51)、T21I+A173V+T304I (55)、L50F+E166A+L167F (210)、T21I+L50F+A193P+S301P (7.3)、L50F+F140L+L167F+T304I(190) 和T21I+C160F+A173V+V186A+T304I
                    (28)。以下出現在細胞培養中的置換和置換組合，在生化測定中使nirmatrelvir活性降低 &lt;3 倍：T21I (1.6)、L50F
                    (0.2)、P108S (2.9)、T135I (2.2)、C160F (0.6)、L167F (0.9)、T169I (1.4)、V186A (0.8)、A191V (0.8)、A193P (0.9)、P252L (0.9)、S301P (0.2)、T304I (1.0)、T21I+T304I (1.8) 和L50F+T304I (1.3)。這些置換的 臨床意義尚不清楚。</p>

                    <p>臨床試驗</p>
                    <p>在臨床試驗 EPIC-HR/SR 中以基準期和基準期後就診時可用的胺基酸序列資料，評估受試者在 治療期間產生的置換（n=907名PAXLOVID治療受試者，n=946名安慰劑治療受試者）。如果 SARS‑CoV‑2 M<sup>pro</sup> 胺基酸變化發生在 3 名或更多名接受 PAXLOVID 治療之受試者的相同胺基 酸位置，並且在 PAXLOVID 治療組比安慰劑治療組中更常見（≥2.5 倍），則此變化可歸類為 PAXLOVID 治療產生的置換。觀察到以下 PAXLOVID 治療產生的 M<sup>pro</sup>置換：T98I/R/del(n=4)、E166V(n=3) 和 W207L/R/del(n=4)。在 M<sup>pro</sup> 切割位點內觀察到以下 PAXLOVID 治療產生的置換：A5328S/V(n=7) 和 S6799A/P/Y (n=4)。這些切割位點置換與任 何特定 M<sup>pro</sup>置換的共同出現無關。</p>
                    
                    <p>這些治療產生的M<sup>pro</sup> 或 M<sup>pro</sup> 切割位點的置換皆未出現在住院接受 PAXLOVID 治療受試者中 。因此，這些置換的臨床意義上不清楚。</p>
                    
                    <p><i>病毒 RNA 反彈（合併或未合併 COVID-19症狀）與治療中出現的置換</i></p>
                    <p>試驗EPIC-HR 和 EPIC-SR 並非旨在評估 COVID-19 反彈；而是進行探索性分析以評估 PAXLOVID治療與病毒 RNA 脫落濃度反彈或自述
                    COVID-19 症狀之間的關係。</p>
                    <p>EPIC-HR和EPIC-SR 試驗中，在PAXLOVID和安慰劑接受者的子群體中觀察到治療後於第10天 和/或第14天時，鼻咽檢體中SARS-CoV-2
                    RNA脫落濃度增加，但此現象與COVID-19症狀無關 。治療後病毒RNA反彈的偵測頻率因分析參數而有所不同，PAXLOVID和安慰劑接受者偵測到</p>
                    <p>的頻率大致上相似。在治療期和治療後期的所有試驗時間點，鼻咽病毒RNA結果低於最低定量 值(&lt;LLOQ)的人數比例，安慰劑接受者與PAXLOVID接受者相近或較低。</p>

                    <p>在試驗EPIC-HR的 59 名接受 PAXLOVID 治療，確定發生治療後病毒 RNA 反彈並獲得可用病 毒序列資料的受試者中，於 2 名 (3%) 受試者偵測到治療產生的 M<sup>pro</sup>置換可能降低 nirmatrelvir 活性，包括其中 1 名受試者出現 E166V， 1 名受試者出現 T304I。到第 14 天為止，兩名受試者的病毒 RNA 脫落濃度 &lt; LLOQ。</p>

                    <p>治療後病毒RNA 反彈與COVID-19 相關的住院的主要臨床結果無關，也與PAXLOVID 單一5 天 療程後第28 天任何原因的死亡無關。PAXLOVID 或安慰劑治療後病毒RNA 增加的臨床相關性 尚不清楚。</p>

                    <p>不論病毒 RNA 結果如何，至第 28 天症狀反彈的頻率在 PAXLOVID 治療組和安慰劑組中相似</p>
                    
                    <p>。由於大多數症狀反彈發生在第 14 天之後（常規評估 SARS‑CoV‑2 RNA 濃度的最後一天），因此無法全面評估病毒 RNA 反彈和症狀反彈的合併頻率。</p>                    
                    
                    <p><i>交叉抗藥性</i></p>                                        
                    <p>Nirmatrelvir 與remdesivir 或任何其他不同作用機制的抗 SARS-CoV-2 藥劑（即非M<sup>pro</sup>抑制 劑的藥劑），預計其不具有交叉抗藥性。</p>                    
                  </div>
                </text>
              </section> 
            </section> 
            <section>
              <title value="12 臨床試驗資料"/>
              <code>
                <coding>
                  <system value="2.16.840.1.113883.6.1"/>
                  <code value=""/>
                  <display value=""/>
                </coding>
              </code>
              <text>
                <status value="generated"/>
                <div xmlns="http://www.w3.org/1999/xhtml"/>
              </text>
              <section>
                <title value="12.1 在可能進展為重症 COVID-19 的高風險受試者中之有效性
                (EPIC-HR)"/>
                <code>
                  <coding>
                    <system value="2.16.840.1.113883.6.1"/>
                    <code value=""/>
                    <display value=""/>
                  </coding>
                </code>
                <text>
                  <status value="generated"/>
                  <div xmlns="http://www.w3.org/1999/xhtml">                    
                    <p>EPIC-HR (NCT04960202)是一項於實驗室確診 SARS-CoV-2 感染的非住院且有症狀的成年受 試者中進行的第 2/3 期、隨機、雙盲、安慰劑對照試驗。納入條件為受試者≥18 歲，且至少具 有以下 1 種會導致進展為重症之風險因素的疾病或情況：糖尿病、體重過重（BMI &gt;25）、慢 性肺病（包括哮喘）、慢性腎臟疾病、目前吸煙、免疫抑制疾病或接受免疫抑制治療，心血管 疾病、高血壓、鐮刀型貧血症、神經發育性疾病、活動性癌症、因醫療需求致機器依賴或無論 是否合併其他疾病者之60 歲或以上的受試者。試驗收納 COVID-19 症狀發作 5 天內之受試者</p>
                    <p>。受試者按 1:1比例，隨機分配至 PAXLOVID （nirmatrelvir/Ritonavir 300 mg/100 mg）組</p>
                    <p>或安慰劑組，每 12 小時口服一次，持續 5 天。本試驗排除了曾感染過COVID-19者或曾接種過 COVID-19疫苗者，也排除了使用任何與PAXLOVID 有顯著臨床藥物交互作用之藥物者。試驗 之主要療效指標是 28 天內發生 因COVID-19 相關原因住院或任何原因導致死亡之受試者比例，並於改良版意圖治療 (mITT) 分析群體（定義為所有在基礎期未接受或預期不會接受 COVID-19 單株抗體治療，且症狀發作3天內並接受試驗藥物治療者）、mITT1 分析群體（定義為所有 在基礎期時未接受或預期不會接受 COVID-19 單株抗體 [mAb] 治療，且症狀發作 5 天內並接</p>
                    <p>受試驗藥物治療者）和 mITT2 分析群體（定義為所有症狀發作 5 天內且接受試驗藥物治療者）進行分析。</p>                    
                    
                    <p>本試驗共收納2,113位受試者，隨機分配至 PAXLOVID 組或安慰劑組。基礎期時受試者之平均 年齡為 45 歲；51% 為男性；71% 為白人，15%為亞洲人，9%為印地安裔美國人或阿拉斯加 原住⺠，4% 為黑人或非裔美國人，1% 為遺漏或未知資料；41% 為⻄班牙裔或拉丁美洲裔；67% 的受試者在治療開始3天內( ≤ 3)出現症狀；49% 的受試者在基準期時血清檢查呈陰性；鼻咽檢體中的基準期病毒RNA平均值 (標準差)為 4.71 log 10 copies/mL (2.89)；27% 的受試 者的基準期病毒RNA ≥ 10^ 7（log 10 copies/mL）；6% 的受試者在隨機分配時接受或預期接 受 COVID-19 單株抗體治療，此類受試者將從 mITT 和 mITT1 分析群體中排除。</p>
                                        
                    <p>PAXLOVID 和安慰劑兩組受試者於基礎期之人口統計學和疾病特徵的分布相似。</p>
                                        
                    <p>因不良事件終止治療的受試者比例在 PAXLOVID 組為 2.0%，在安慰劑組為
                    4.2%。</p>                    
                    
                    <p>表 8 提供了主要療效指標於 mITT1 分析群體的結果。與安慰劑相比，PAXLOVID針對主要療效 指標於 mITT1 分析群體的風險相對降低了 86% (95% CI: 72%, 93%)。</p>
                    
                    <p>表 8：至第28天，因COVID-19相關問題住院或因任何原因死亡之非住院成年COVID-19病</p>
                    <!-- Table Placeholder-->
                    
                    <p>縮寫：CI = 信賴區間；COVID-19 = 2019新型冠狀病毒疾病；mAb = 單株抗體；mITT1 = 改良版意圖治療 1（所有在基期時未接受也預期不會接受 COVID-19 mAb 治療，且出現症狀 ≤5 天的接受治療受試者）。</p>
                    <p>PAXLOVID療效的確定主要是依據事先訂定的期間分析結果，即754位mITT 群體之分析結 果。其風險降低比例的估計值為 -6.5%，95% CI (-9.3%, -3.7%)，雙尾 p 值 &lt; 0.0001。</p>
                    <p>a. 採用 Kaplan-Meier 方法計算每個治療組別 28 天內住院或死亡的受試者累積比例之估 計值，但28 天內沒有住院和死亡之受試者則於試驗終止時視為設限(censored)資料。</p>
                    
                    <p>b. 至第 24 週的全因死亡率次要指標，PAXLOVID  組和安慰劑組分別有 0 起和 15 起 (1%) 不良事件。</p>                    
                    
                    <p>於mITT 和 mITT2 分析群體中亦觀察到一致的結果。</p>
                    <p>在受試者次群體分析中觀察到相似的趨勢（見圖 1）。</p>

                    <p><b>圖 1：至第 28 天，COVID-19 症狀發作後 5 天內接受給藥且因 COVID‑19 相關住院或全因死</b> 亡成人的次群體分析：EPIC-HR</p>
                    <p><img src="#category" alt="Subpopulation analysis"/></p>                    
                    <p>縮寫：BMI = 身體質量指數；COVID-19 = 2019 新型冠狀病毒疾病；mAb = 單株抗體；mITT = 改良版意圖治療；SARS-CoV-2 = 嚴重急性呼吸道症候群冠狀病毒 2 型。</p>
                    <p>N = 分析群體中各類別之受試者人數。所有類別均基於 mITT1 群體，惟是否接受COVID-19 單株抗體治療類別之療效是基於 mITT2 群體。</p>
                    <p>如果在 Elecsys 抗 SARS-CoV-2 S 或 Elecsys 抗 SARS-CoV-2(N) 測定中結果為陽性，則定義 血清陽性。</p>
                    <p>上圖列出了 2 個治療組別間的比例差異及其差異之常態近似的 95% 信賴區間。</p>                   
                    
                    <p>基準期時 SARS-CoV-2 血清檢測呈陽性的受試者中，490 位PAXLOVID 接受者中有1位 (0.2%)，以及479 位安慰劑接受者中有8位(1.7%)，在第 28 天達到了 COVID-19 相關住院或因 任何原因死亡的主要指標 [相對於安慰劑減少 -1.47% (-2.70%, -0.25%)]。</p>
                  </div>
                </text>
              </section> 
              <section>
                <title value="12.2 針對不具有進展為重症 COVID-19 之風險因子，且未接種疫苗的受試者，或已完整接種"/>
                <code>
                  <coding>
                    <system value="2.16.840.1.113883.6.1"/>
                    <code value=""/>
                    <display value=""/>
                  </coding>
                </code>
                <text>
                  <status value="generated"/>
                  <div xmlns="http://www.w3.org/1999/xhtml">
                    <p>COVID-19 疫苗但至少有一個進展為重症 COVID-19 風險因子的受試者進行的試驗 (EPIC-SR)</p>
                      <p>PAXLOVID 不適用於沒有進展為嚴重 COVID-19 的風險因子病人的 COVID-19 治療。</p>
                      
                      
                      <p>EPIC-SR (NCT05011513) 是一項於實驗室確診 SARS-CoV-2 感染的非住院且有症狀的成年受 試者中已進行的第 2/3 期、隨機分配、雙盲、安慰劑對照試驗。符合資格的受試者為 18 歲或 以上且出現 COVID-19 症狀 ≤5 天，並處於惡化為重症的一般風險中。該試驗包括先前未接種 疫苗但無進展為重症之風險因子的受試者，或已完整接種 COVID-19 疫苗（即完成初級疫苗接 種系列）至少且有1 個進展為重症之風險因子（如
                      EPIC-HR定義）的受試者。至2021年12月 19日資料截斷點為止，共有 1,075 名受試者進行隨機分配 (1:1) 至口服 PAXLOVID  或安慰劑，每 12 小時一次並持續 5 天；其中，59% 為已完整接種疫苗的高風險受試者。</p>
                      
                      
                      <p>試驗的主要指標，即至第28天為止，PAXLOVID 與安慰劑接受者所有目標 COVID-19徵兆和症 狀維持緩解時間的差異，並未達到。</p>
                      
                      
                      <p>在對至少有 1 個進展為重症之風險因子，且已完整接種疫苗的受試者次群體進行的探索性分析 中，與安慰劑相比，至第28天為止，觀察到因COVID-19 相關因素住院或因任何原因死亡的次 要指標減少數字不具統計學顯著性。</p>                      
                  </div>
                </text>
              </section> 
            </section> 
            <section>
              <title value="13 包裝及儲存"/>
              <code>
                <coding>
                  <system value="2.16.840.1.113883.6.1"/>
                  <code value=""/>
                  <display value=""/>
                </coding>
              </code>
              <text>
                <status value="generated"/>
                <div xmlns="http://www.w3.org/1999/xhtml"/>
              </text>
            </section> 
            <section>
              <title value="13.1 包裝"/>
              <code>
                <coding>
                  <system value="2.16.840.1.113883.6.1"/>
                  <code value=""/>
                  <display value=""/>
                </coding>
              </code>
              <text>
                <status value="generated"/>
                <div xmlns="http://www.w3.org/1999/xhtml">
                  <p><i>供應方式</i></p>
                  <p>PAXLOVID 採用 nirmatrelvir 錠劑與ritonavir錠劑組合包裝。</p>
                  <ul>
                    <li><p>Nirmatrelvir 150 mg 錠劑為橢圓形、粉紅色膜衣錠，一側刻有“PFE”字樣，另一側刻有 “3CL”字樣。</p></li>
                    <li><p>Ritonavir 100 mg 錠劑為白色至灰白色橢圓形膜衣錠，一側刻有“H”字樣，另一側刻有 “R9” 字樣。</p></li>
                  </ul>
                  
                  <p>Nirmatrelvir 錠劑和ritonavir錠劑裝於同一個兒童安全泡殼卡內的單獨泡殼中。</p>
                  
                  <p>每盒含 30 顆錠劑，分成 5 日劑量泡殼卡。</p>
                  
                  <p>每日泡殼卡含 4  顆 nirmatrelvir錠劑（各 150 mg）和 2 顆ritonavir錠劑（各 100 mg），說明 需要在早晨和晚上分別服用哪些錠劑。</p>
                </div>
              </text>
              <section>
                <title value="13.2 效期"/>
                <code>
                  <coding>
                    <system value="2.16.840.1.113883.6.1"/>
                    <code value=""/>
                    <display value=""/>
                  </coding>
                </code>
                <text>
                  <status value="generated"/>
                  <div xmlns="http://www.w3.org/1999/xhtml">
                    <p>如外包裝所示。</p>
                  </div>
                </text>
                <section>
                  <title value="13.3 儲存條件"/>
                  <code>
                    <coding>
                      <system value="2.16.840.1.113883.6.1"/>
                      <code value=""/>
                      <display value=""/>
                    </coding>
                  </code>
                  <text>
                    <status value="generated"/>
                    <div xmlns="http://www.w3.org/1999/xhtml">
                      <p>儲存和處理</p>
                      <p>儲存於 25°C以下。</p>                      
                    </div>
                  </text>
                </section> 
            </section> 
          </section>
        </section> 
        </section>
        <section>
          <title value="PATIENT MEDICATION INFORMATION "/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value="68498-5"/>
              <display value="PATIENT MEDICATION INFORMATION"/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p style="text-align:center">病人使用須知</p>
              <p style="text-align:center">倍拉維150毫克/100毫克膜衣錠</p>
              <p style="text-align:center">(nirmatrelvir tablets; ritonavir tablets)</p>
              <p style="text-align:center">組合包裝供口服使用</p>

                <table>
                  <tr>
                    <td colspan="3">
                      <p>什麼是我應該知道關於 PAXLOVID 最重要的資訊</p>
                      <p>PAXLOVID 可能會和其他藥物產生交互作用，造成嚴重或危及生命的副作用或死亡。了解哪些藥物不應該與 PAXLOVID 共同使用是非常重要的。 </p>
                      <p>不該服用PAXLOVID的情況：</p>
                      <p>•	您正在服用任何下列藥物： </p>
                    </td>
                  </tr>
                    <tr>
                        <td>o alfuzosin</td>
                        <td>o amiodarone</td>
                        <td>o apalutamide</td>
                    </tr>
                    <tr>
                        <td>o carbamazepine</td>
                        <td>o colchicine</td>
                        <td>o dihydroergotamine</td>
                    </tr>
                    <tr>
                        <td>o dronedarone</td>
                        <td>o eletriptan</td>
                        <td>o eplerenone</td>
                    </tr>
                    <tr>
                        <td>o ergotamine</td>
                        <td>o finerenone</td>
                        <td>o flecainide</td>
                    </tr>
                    <tr>
                        <td>o flibanserin</td>
                        <td>o ivabradine</td>
                        <td>o lomitapide</td>
                    </tr>
                    <tr>
                        <td>o lovastatin</td>
                        <td>o lumacaftor/ivacaftor</td>
                        <td>o lurasidone</td>
                    </tr>
                    <tr>
                        <td>o methylergonovine</td>
                        <td>o midazolam (oral)</td>
                        <td>o naloxegol</td>
                    </tr>
                    <tr>
                        <td>o phenobarbital</td>
                        <td>o phenytoin</td>
                        <td>o pimozide</td>
                    </tr>
                    <tr>
                        <td>o primidone</td>
                        <td>o propafenone</td>
                        <td>o quinidine</td>
                    </tr>
                    <tr>
                        <td>o ranolazine</td>
                        <td>o rifampin</td>
                        <td>o rifapentine</td>
                    </tr>
                    <tr>
                        <td>o St. John’s Wort (hypericum perforatum)</td>
                        <td>o sildenafil (Revatio®) for pulmonary arterial hypertension</td>
                        <td>o silodosin</td>
                    </tr>
                    <tr>
                        <td>o simvastatin</td>
                        <td>o tolvaptan</td>
                        <td>o triazolam</td>
                    </tr>
                    <tr>
                        <td>o ubrogepant</td>
                        <td>o voclosporin</td>
                        <td></td>
                    </tr>
                </table>
            <p>如果與 PAXLOVID 一起服用，並不是只有這些藥物可能會導致嚴重副作用。PAXLOVID 可能會增加或減少多種其他藥物的濃度。請務必告訴您的醫療照護提供者您正在使用的所有藥物，這非常重要，因為在 PAXLOVID 療程中，可能需要進行額外的實驗室檢測或變更其他藥物的劑量。您的醫療照護提供者也可能會告訴您有關需要注意的特定症狀，這些可能表示您需要停止或減少某些其他藥物的劑量。</p>
            <p>•	您對 nirmatrelvir、ritonavir或 PAXLOVID 中的任何成分過敏。PAXLOVID 完整成分清單請參見本文件結尾處。過敏反應的徵兆和症狀請參見「PAXLOVID 可能產生的重要副作用有哪些？」。</p>
            <p>PAXLOVID是甚麽藥物？</p>
            <p>PAXLOVID是一種處方藥，用 於治療12歲以上、具有進展為重症風險因子之輕度至中度新型冠狀病毒疾病(COVID-19) 病人。</p>
            <p>PAXLOVID未被核准用於 COVID-19 的暴露前或暴露後的預防治療。</p>
            <p>服用PAXLOVID前，務必告知醫療照護提供者您的所有醫療狀況，包括您是否：</p>
            <ul>
              <li>有腎臟問題。您可能需要不同劑量的PAXLOVID。</li>
              <li>有肝臟問題，包括肝炎。</li>
              <li>感染人類免疫缺乏病毒 1 (HIV-1)。PAXLOVID 可能會導致一些 HIV-1 藥物日後無法發揮作用。</li>
              <li>已懷孕或計劃懷孕。目前不清楚 PAXLOVID 是否會傷害您未出生的嬰兒。如果您正在懷孕或發現懷孕，請立刻告知您的醫療照護提供者。</li>
              <li>正在哺乳或計劃哺乳。目前不清楚 PAXLOVID 是否會進入您的母乳。請與您的醫療照護提供者討論在 PAXLOVID 治療期間哺餵您嬰兒的最佳方式。</li>
            </ul>
            <p>告知醫療照護提供者所有您服用的藥物，包括處方藥及非處方藥、維生素及草藥類補充劑。</p>
            <ul>
              <li>您的醫療照護提供者可以告訴您 PAXLOVID 與其他藥物一起使用是否安全。</li>
              <li>您可以向醫療照護提供者或藥師索取與PAXLOVID產生相互作用的藥物清單。</li>
              <li>請勿在沒有告訴您的醫療照護提供者的情況下開始服用新的藥物。</li>
            </ul> 
            <p>如果您正在服用複方避孕藥（荷爾蒙避孕藥），請告訴您的醫療照護提供者。PAXLOVID 可能會影響您的荷爾蒙避孕藥的作用。具生育力的女性應在 PAXLOVID 治療期間使用另一種有效的替代避孕方式或額外的阻隔避孕法。如果您對可能適合您的避孕方法有任何疑問，請與您的醫療照護提供者討論。</p>
            <p>我應如何服用PAXLOVID？</p>
            <ul>
              <li>完全遵照您的醫療照護提供者告訴您的方式服用 PAXLOVID。</li>
              <li>PAXLOVID 由 2 種藥物組成：nirmatrelvir 錠劑和 ritonavir 錠劑。每天服用兩種藥物兩次，持續 5 天。
                <ul>
                  <li>Nirmatrelvir是一種橢圓型、粉紅色的錠劑。</li>
                  <li>Ritonavir是一種白色或灰白色錠劑。</li>
                </ul>
              </li>
              <li>如果您患有腎臟疾病，請與您的醫療照護提供者討論。您 可能會需要不一樣的劑量。</li>
              <li>除非您準備服用您的劑量，否則請勿打開PAXLOVID錠劑的泡殼包裝。
                <ul>
                  <li>在早上或睡前服用第一劑PAXLOVID，取決於您何時取得處方藥物，或者按照醫療照護提供者告訴您的方式。</li>
                  <li>針對每次劑量，同時服用所有 3 顆錠劑。</li>
                </ul>
              </li>
              <li>錠劑應整粒吞服。不得咀嚼、破壞或壓碎錠劑。</li>
              <li>可隨餐或空腹服用 PAXLOVID。</li>
              <li>即使您感覺好多了，請勿在沒有和您的醫療照護提供者討論的情況下停止服用PAXLOVID。</li>
              <li>如果您在平常服用的 8 小時內漏服一劑 PAXLOVID，一旦您記起來就請立即服用它。如果您漏服一劑超過 8 小時，請跳過漏服的劑量，並在您例行的時間服用下一劑。請勿同時服用 2 劑 PAXLOVID。</li>
              <li>如果您服用太多 PAXLOVID，請立即聯絡您的醫療照護提供者或前往最近的醫院急診室。</li>
              <li>如果您正在服用含 ritonavir 或 cobicistat 的藥物來治療 C 型肝炎或 HIV-1 感染，您應該繼續服用由醫療照護提供者開立給您的藥物。</li>
             </ul>
             <p>如果您感覺沒有改善或 5 天後感覺惡化，請與您的醫療照護提供者討論。</p>
             <p>PAXLOVID 可能產生的重要副作用有哪些？</p>
             <p>PAXLOVID 可能會造成嚴重副作用，包括:</p>
             <p>•	過敏反應，包括嚴重的過敏反應（急性過敏），曾發生於 PAXLOVID 治療期間。如果您發生任何下列過敏反應的症狀，請停止服用 PAXLOVID 並立即尋求醫療協助：</p>
             <table border="0">
              <tr>
              </tr>
              <tr>
                  <td>o	皮疹、蕁麻疹、水泡或脫皮</td>
                  <td>o	吞嚥或呼吸困難</td>
              </tr>
              <tr>
                  <td>o	嘴巴、鼻子、喉嚨或生殖器部位出現疼痛性瘡或潰瘍</td>
                  <td>o	喉嚨發緊</td>
              </tr>
              <tr>
                  <td>o	嘴、嘴唇、舌頭或臉部腫脹</td>
                  <td>o	聲音嘶啞</td>
              </tr>
          </table>
          <p>•	肝臟問題。若您在使用PAXLOVID進行治療期間出現任何下列與肝臟問題有關的體徵和症狀，請立即告知醫療照護提供者：</p>
          <table border="0">
            <tr>
            </tr>
            <tr>
                <td>o	食慾不振</td>
                <td>o	淺色糞便</td>
            </tr>
            <tr>
                <td>o	皮膚和眼白泛黃 </td>
                <td>o	皮膚搔癢</td>
            </tr>
            <tr>
                <td>o	深色尿液</td>
                <td>o	胃部（腹部）疼痛</td>
            </tr>
        </table>
        <p>PAXLOVID的最常見副作用包括：味覺改變和腹瀉。</p>
        <p>其他可能的副作用包括：</p>
        <ul>
          <li>頭痛</li>
          <li>嘔吐</li>
          <li>腹痛</li>
          <li>噁心</li>
          <li>高血壓</li>
          <li>整體感覺不適</li>
        </ul>
        <p>這些並非 PAXLOVID 所有的可能副作用。欲知更多資訊，請詢問您的醫療照護提供者或藥師。</p>
        <p>我應該如何存放PAXLOVID？</p>
        <ul>
          <li>在室溫下儲存 PAXLOVID 錠劑，溫度為 25○C以下。</li>
        </ul>
        <p>請將PAXLOVID和所有藥物放在兒童接觸不到的地方。</p>
        <p>關於安全有效使用PAXLOVID的一般資訊</p>
        <p>有時會為了本文件中未列出的其他目的開立處方藥。請勿將PAXLOVID用於未開具處方的病症。請勿將PAXLOVID給其他人服用，即使他們出現相同的症狀，可能會對他們造成傷害。您可以向您的醫療照護提供者或藥師諮詢為醫療專業人員撰寫的有關PAXLOVID的資訊。</p>
        <p>PAXLOVID的成分有哪些？</p>
        <p>活性成分：nirmatrelvir 和 ritonavir</p>
        <p>Nirmatrelvir 非活性成分：colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, and sodium stearyl fumarate。膜衣內含：hydroxy propyl methylcellulose, iron oxide red, polyethylene glycol, and titanium dioxide。</p>
        <p>Ritonavir 非活性成分：copovidone, sorbitan laurate, silica colloidal anhydrous, calcium hydrogen phosphate anhydrous and sodium stearyl fumarate。膜衣內含：hypromellose, titanium dioxide, macrogol, hydroxypropyl cellulose, talc, silica colloidal anhydrous and polysorbate 80。</p>
        <p>版本: USPI 202305-1</p>
      </div>
          </text>
        </section>  
          <section>
            <title value="SPL UNCLASSIFIED SECTION"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="34066-1"/>
                <display value="OTHER"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>其他</p>
                <p>版本: USPI 202305-2</p>
                <p>  </p>
                <p>Nirmatrelvir 150 mg Film-Coated Tablets製造廠(一)：Pfizer Manufacturing Deutschland GmbH</p>
                <p>廠址：Betriebsstätte Freiburg, Mooswaldallee 1, D-79090 Freiburg, Germany.</p>
                <p>Nirmatrelvir 150 mg Film-Coated Tablets製造廠(二)：Pfizer Italia S.r.L</p>
                <p>廠址：Localita Marino Del Tronto, 63100, Ascoli Piceno, Italy.</p>
                <p>  </p>
                <p>Ritonavir 100 mg Film-Coated Tablets製造廠：Hetero Labs Ltd., Unit III</p>
                <p>廠址：22-110, Industrial Development Area, Jeedimetla, Hyderabad, Telangana, India, 500055.</p>
                <p>Ritonavir 100 mg Film-Coated Tablets分包裝廠 (一)：Pfizer Manufacturing Deutschland GmbH</p>
                <p>廠址：Betriebsstätte Freiburg,Mooswaldallee 1, D-79090 Freiburg, Germany.</p>
                <p>Ritonavir 100 mg Film-Coated Tablets分包裝廠 (二)：Pfizer Italia S.r.L</p>
                <p>廠址：Localita Marino Del Tronto, 63100, Ascoli Piceno, Italy.</p>
                <p>  </p>
                <p>藥    商:輝瑞大藥廠股份有限公司</p>
                <p>地    址:台北市信義區松仁路100號42、43樓</p>
              </div>
            </text>
          </section>
        </section>
        </section>
        </section> 
        
    
      </Composition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="RegulatedAuthorization/authorizationpaxlovid" />
    <resource>
      <RegulatedAuthorization>
        <id value="authorizationpaxlovid" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi" />
        </meta>
        <identifier>
          <use value="official" />
          <system value="https://spor.ema.europa.eu/pmswi" />
          <value value="6ae5b5d9-7372-494c-874b-7dc67d386d2e" />
        </identifier>
        <subject>
          <reference value="MedicinalProductDefinition/cfaeff60-72ff-42e0-bf17-d56db0f2da16" />
        </subject>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi" />
            <code value="220000000061" />
            <display value="Marketing Authorisation" />
          </coding>
        </type>
        <region>
          <coding>
            <system value="urn:iso:std:iso:3166" />
            <code value="TW" />
            <display value="Taiwan" />
          </coding>
        </region>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status" />
            <code value="active" />
            <display value="Active" />
          </coding>
        </status>
        <statusDate value="2022-03-01T00:00:00Z" />
        <holder>
          <reference value="Organization/e7fec37a-af43-4b91-9ec3-e7b2c5cb869b" />
        </holder>
      </RegulatedAuthorization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:e7fec37a-af43-4b91-9ec3-e7b2c5cb869b"/>
    <resource>
      <Organization>
        <id value="e7fec37a-af43-4b91-9ec3-e7b2c5cb869b"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://mcp.fda.gov.tw/"/>
          <value value="e7fec37a-af43-4b91-9ec3-e7b2c5cb869b"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="220000000034"/>
            <display value="Marketing authorisation holder"/>
          </coding>
        </type>
        <name value="輝瑞大藥廠股份有限公司"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="台北市信義區松仁路100號42、43樓"/>
            <line value="台北市信義區松仁路100號42、43樓"/>
            <city value="台北市"/>
            <country value="TW"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:a773ccac-5988-4a1d-9723-17bd58eb7a36"/>
    <resource>
      <Organization>
        <id value="a773ccac-5988-4a1d-9723-17bd58eb7a36"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://mcp.fda.gov.tw/"/>
          <value value="a773ccac-5988-4a1d-9723-17bd58eb7a36"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="220000000033"/>
            <display value="Manufacturer"/>
          </coding>
        </type>
        <name value="Pfizer Manufacturing Deutschland GmbH"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="Mooswaldallee 1, Bruehl, Freiburg Im Breisgau, Baden-Wuerttemberg, 79108, Germany"/>
            <line value="Mooswaldallee 1, Bruehl, Freiburg Im Breisgau, Baden-Wuerttemberg"/>
            <city value="Freiburg Im Breisgau"/>
            <country value="DE"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:123f09dd-7fbd-415e-966a-cf2c8ae08cc8"/>
    <resource>
      <Organization>
        <id value="123f09dd-7fbd-415e-966a-cf2c8ae08cc8"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://mcp.fda.gov.tw/"/>
          <value value="123f09dd-7fbd-415e-966a-cf2c8ae08cc8"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="220000000033"/>
            <display value="Manufacturer"/>
          </coding>
        </type>
        <name value="Pfizer Italia S.r.L"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="Localita Marino Del Tronto, Ascoli Piceno, AP, 63100, Italy"/>
            <line value="Localita Marino Del Tronto"/>
            <city value="Ascoli Piceno"/>
            <country value="IT"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:98978892-7f39-4f51-a7e9-fa2bd11c171d"/>
    <resource>
      <Organization>
        <id value="98978892-7f39-4f51-a7e9-fa2bd11c171d"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://mcp.fda.gov.tw/"/>
          <value value="98978892-7f39-4f51-a7e9-fa2bd11c171d"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="220000000033"/>
            <display value="Manufacturer"/>
          </coding>
        </type>
        <name value="Hetero Labs Ltd., Unit III"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="22-110, Industrial Development Area, Jeedimetla, Hyderabad, Telangana, India, 500055."/>
            <line value="22-110, Industrial Development Area"/>
            <city value="Telangana"/>
            <country value="IN"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:cfaeff60-72ff-42e0-bf17-d56db0f2da16"/>
    <resource>
      <MedicinalProductDefinition>
        <id value="cfaeff60-72ff-42e0-bf17-d56db0f2da16"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
        </meta>
        <identifier>
          <system value="https://mcp.fda.gov.tw/"/>
          <value value="cfaeff60-72ff-42e0-bf17-d56db0f2da16"/>
        </identifier>
        <type>
          <coding>
            <system value="http://hl7.org/fhir/medicinal-product-type"/>
            <code value="MedicinalProduct"/>
            <display value="医药产品"/>
          </coding>
        </type>
        <domain>
          <coding>
            <system value="http://hl7.org/fhir/medicinal-product-domain"/>
            <code value="Human"/>
            <display value="人类使用"/>
          </coding>
        </domain>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
            <display value="Active"/>
          </coding>
        </status>
        <statusDate value="2024-01-31T00:00:00Z"/>
        <legalStatusOfSupply>
          <coding>
            <system value="http://hl7.org/fhir/legal-status-of-supply"/>
            <code value="100000072084"/>
            <display value="药品须遵守医生处方"/>
          </coding>
        </legalStatusOfSupply>
        <classification>
					<coding>
						<system value="http://hl7.org/fhir/ValueSet/medicinal-product-classification"/>
						<code value="J05AE30"/>
						<display value="抗病毒药物 蛋白酶抑制剂"/>
					</coding>
				</classification>
        <route>
					<coding>
						<system value="http://hl7.org/fhir/uv/emedicinal-product-info/ValueSet/routeOfAdministration"/>
						<code value="26643006"/>
						<display value="口服途径"/>
					</coding>
				</route>
        <name>
          <productName value="倍拉維150毫克/100毫克膜衣錠"/>
          <usage>
            <country>
              <coding>
                <system value="http://hl7.org/fhir/ValueSet/country"/>
                <code value="TW"/>
                <display value="Taiwan"/>
              </coding>
            </country>
            <jurisdiction>
              <coding>
                <system value="http://hl7.org/fhir/ValueSet/jurisdiction"/>
                <code value="TW"/>
                <display value="Taiwan"/>
              </coding>
            </jurisdiction>
            <language>
              <coding>
                <system value="http://hl7.org/fhir/ValueSet/all-languages"/>
                <code value="zh"/>
                <display value="Chinese"/>
              </coding>
            </language>
          </usage>
        </name>
      </MedicinalProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:9597af0f-64da-44eb-a05a-b302e2e5eb1d"/>
    <resource>
      <PackagedProductDefinition>
        <id value="9597af0f-64da-44eb-a05a-b302e2e5eb1d"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://mcp.fda.gov.tw/"/>
          <value value="594b9632-affb-4108-88ac-caad7541af00"/>
        </identifier>
        <name value="倍拉維150毫克/100毫克膜衣錠 吸塑包装 x 30 顆錠劑"/>
        <type>
          <coding>
            <system value="http://hl7.org/fhir/medicinal-product-type"/>
            <code value="MedicinalProduct"/>
            <display value="医药产品"/>
          </coding>
        </type>
        <packageFor>
          <reference value="urn:uuid:cfaeff60-72ff-42e0-bf17-d56db0f2da16"/>
        </packageFor>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
            <display value="Active"/>
          </coding>
        </status>
        <statusDate value="2024-01-31T00:00:00Z"/>
        <containedItemQuantity>
          <value value="150"/>
          <unit value="毫克"/>
        </containedItemQuantity>
        <packaging>
          <identifier>
            <system value="https://mcp.fda.gov.tw/"/>
            <value value="aeae17de-9dd9-4f67-86ad-2c078f60a445"/>
          </identifier>
          <type>
            <coding>
              <system value="http://hl7.org/fhir/medicinal-product-package-type"/>
              <code value="100000073496"/>
              <display value="吸塑包装"/>
            </coding>
          </type>
          <quantity value="30"/>
          <material>
            <coding>
              <system value="http://hl7.org/fhir/package-material"/>
              <code value="200000003210"/>
              <display value="Orientated PolyAmide"/>
            </coding>
            <coding>
              <system value="http://hl7.org/fhir/package-material"/>
              <code value="200000003200"/>
              <display value="Aluminium"/>
            </coding>
            <coding>
              <system value="http://hl7.org/fhir/package-material"/>
              <code value="200000003222"/>
              <display value="PolyVinyl Chloride"/>
            </coding>
          </material>
        </packaging>
      </PackagedProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:4e0f663a-3b69-41cf-a3c0-416206d0deee"/>
    <resource>
      <AdministrableProductDefinition>
        <id value="4e0f663a-3b69-41cf-a3c0-416206d0deee"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi"/>
        </meta>
        <identifier>
          <system value="https://www.who-umc.org/phpid"/>
          <value value="236b14ee-38bc-41ec-801a-b2c229a75e64"/>
        </identifier>
        <status value="active"/>
        <formOf>
          <reference value="urn:uuid:cfaeff60-72ff-42e0-bf17-d56db0f2da16"/>
        </formOf>
        <administrableDoseForm>
          <coding>
            <system value="http://hl7.org/fhir/administrable-dose-form"/>
            <code value="100000073665"/>
            <display value="膜衣錠"/>
          </coding>
        </administrableDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="http://hl7.org/fhir/unit-of-presentation"/>
            <code value="200000002152"/>
            <display value="顆錠劑"/>
          </coding>
        </unitOfPresentation>
        <producedFrom>
          <reference value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        </producedFrom>
        <routeOfAdministration>
          <code>
            <coding>
              <system value="http://snomed.info/sct"/>
              <code value="26643006"/>
              <display value="口服途径"/>
            </coding>
          </code>
        </routeOfAdministration>
      </AdministrableProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:391fe0c6-50cc-45df-86ef-e0ec7cf6ab7f"/>
    <resource>
      <AdministrableProductDefinition>
        <id value="391fe0c6-50cc-45df-86ef-e0ec7cf6ab7f"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi"/>
        </meta>
        <identifier>
          <system value="https://www.who-umc.org/phpid"/>
          <value value="10f671c1-cec0-4d00-9dfe-316b76804b6c"/>
        </identifier>
        <status value="active"/>
        <formOf>
          <reference value="urn:uuid:cfaeff60-72ff-42e0-bf17-d56db0f2da16"/>
        </formOf>
        <administrableDoseForm>
          <coding>
            <system value="http://hl7.org/fhir/administrable-dose-form"/>
            <code value="100000073665"/>
            <display value="膜衣錠"/>
          </coding>
        </administrableDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="http://hl7.org/fhir/unit-of-presentation"/>
            <code value="200000002152"/>
            <display value="顆錠劑"/>
          </coding>
        </unitOfPresentation>
        <producedFrom>
          <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </producedFrom>
        <routeOfAdministration>
          <code>
            <coding>
              <system value="http://snomed.info/sct"/>
              <code value="26643006"/>
              <display value="口服途径"/>
            </coding>
          </code>
        </routeOfAdministration>
      </AdministrableProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
    <resource>
      <ManufacturedItemDefinition>
        <id value="3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://mcp.fda.gov.tw/"/>
          <value value="473f236d-9d51-47e7-9e27-576be2c266a1"/>
        </identifier>
        <name value="Nirmatrelvir 150毫克膜衣錠"/>
        <status value="active"/>
        <manufacturedDoseForm>
          <coding>
            <system value="http://hl7.org/fhir/manufactured-dose-form"/>
            <code value="100000073665"/>
            <display value="膜衣錠"/>
          </coding>
        </manufacturedDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="http://hl7.org/fhir/unit-of-presentation"/>
            <code value="200000002152"/>
            <display value="顆錠劑"/>
          </coding>
        </unitOfPresentation>
        <manufacturer>
          <reference value="urn:uuid:a773ccac-5988-4a1d-9723-17bd58eb7a36"/>
        </manufacturer> 
        <manufacturer>
          <reference value="urn:uuid:123f09dd-7fbd-415e-966a-cf2c8ae08cc8"/>
        </manufacturer>
      </ManufacturedItemDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
    <resource>
      <ManufacturedItemDefinition>
        <id value="c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://mcp.fda.gov.tw/"/>
          <value value="3ab80f4d-3932-47cd-89c6-c480006fd7cc"/>
        </identifier>
        <name value="Ritonavir 100毫克膜衣錠"/>
        <status value="active"/>
        <manufacturedDoseForm>
          <coding>
            <system value="http://hl7.org/fhir/manufactured-dose-form"/>
            <code value="100000073665"/>
            <display value="膜衣錠"/>
          </coding>
        </manufacturedDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="http://hl7.org/fhir/unit-of-presentation"/>
            <code value="200000002152"/>
            <display value="顆錠劑"/>
          </coding>
        </unitOfPresentation>
        <manufacturer>
          <reference value="urn:uuid:98978892-7f39-4f51-a7e9-fa2bd11c171d"/>
        </manufacturer>
        <manufacturer>
          <reference value="urn:uuid:a773ccac-5988-4a1d-9723-17bd58eb7a36"/>
        </manufacturer>
        <manufacturer>
          <reference value="urn:uuid:123f09dd-7fbd-415e-966a-cf2c8ae08cc8"/>
        </manufacturer>
      </ManufacturedItemDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:745c01bc-936e-45ca-9880-57e97608f43e"/>
    <resource>
      <Ingredient>
        <id value="745c01bc-936e-45ca-9880-57e97608f43e"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="7R9A5P7H32"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072072"/>
            <display value="Active"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="7R9A5P7H32"/>
                <display value="Nirmatrelvir"/>
              </coding>
            </concept>
          </code>
          <strength>
            <presentationQuantity>
              <value value="150"/>
              <unit value="毫克"/>
            </presentationQuantity>
            <basis>
              <coding>
                <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
                <code value="ACTI"/>
              </coding>
              <text value="active ingredient"/>
            </basis>
          </strength>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:792d123b-b476-4846-8c37-257cb02015f8"/>
    <resource>
      <Ingredient>
        <id value="792d123b-b476-4846-8c37-257cb02015f8"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="O3J8G9O825"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072072"/>
            <display value="Active"/>
          </coding>
        </role>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="O3J8G9O825"/>
                <display value="Ritonavir"/>
              </coding>
            </concept>
          </code>
          <strength>
            <presentationQuantity>
              <value value="100"/>
              <unit value="毫克"/>
            </presentationQuantity>
            <basis>
              <coding>
                <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
                <code value="ACTI"/>
              </coding>
              <text value="active ingredient"/>
            </basis>
          </strength>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:09c13040-8fd5-4818-972d-f01d4ee169b6"/>
    <resource>
      <Ingredient>
        <id value="09c13040-8fd5-4818-972d-f01d4ee169b6"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="ETJ7Z6XBU4"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="ETJ7Z6XBU4"/>
                <display value="Silicon dioxide, colloidal"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:80c1871d-955b-452c-b486-1c008a49f94e"/>
    <resource>
      <Ingredient>
        <id value="80c1871d-955b-452c-b486-1c008a49f94e"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="M28OL1HH48"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="M28OL1HH48"/>
                <display value="Croscarmellose sodium"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:87772b11-f10f-4000-bcc5-6331da1317d9"/>
    <resource>
      <Ingredient>
        <id value="87772b11-f10f-4000-bcc5-6331da1317d9"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="EWQ57Q8I5X"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="EWQ57Q8I5X"/>
                <display value="Lactose monohydrate"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:a70e0d77-7023-4f0a-8543-29b88b79e3fb"/>
    <resource>
      <Ingredient>
        <id value="a70e0d77-7023-4f0a-8543-29b88b79e3fb"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="OP1R32D61U"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="OP1R32D61U"/>
                <display value="Microcrystalline cellulose"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:d0ec45e8-1b9a-4ffb-af8c-a3cbf40b7cbd"/>
    <resource>
      <Ingredient>
        <id value="d0ec45e8-1b9a-4ffb-af8c-a3cbf40b7cbd"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="7CV7WJK4UI"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="7CV7WJK4UI"/>
                <display value="Sodium stearyl fumarate"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:5a2530c8-4599-4fb3-b0e2-df8b29b03bba"/>
    <resource>
      <Ingredient>
        <id value="5a2530c8-4599-4fb3-b0e2-df8b29b03bba"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="3NXW29V3WO"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="3NXW29V3WO"/>
                <display value="Hydroxypropyl methylcellulose"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:b717362f-5bdc-4618-8e40-81171e75cd2d"/>
    <resource>
      <Ingredient>
        <id value="b717362f-5bdc-4618-8e40-81171e75cd2d"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="1K09F3G675"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="1K09F3G675"/>
                <display value="Iron oxide red"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:9d9a4607-9728-40f5-9f0f-3f190416a527"/>
    <resource>
      <Ingredient>
        <id value="9d9a4607-9728-40f5-9f0f-3f190416a527"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="3WJQ0SDW1A"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="3WJQ0SDW1A"/>
                <display value="Polyethylene glycol"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:3fc6c9e0-da0f-44d6-93b7-16590597f7b6"/>
    <resource>
      <Ingredient>
        <id value="3fc6c9e0-da0f-44d6-93b7-16590597f7b6"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="15FIX9V2JP"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:3214f286-b8ec-4ef5-bc8d-0aec39d97468"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="15FIX9V2JP"/>
                <display value="Titanium Dioxide"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:dacf1690-984b-4b75-b39c-9ab42f0ed662"/>
    <resource>
      <Ingredient>
        <id value="dacf1690-984b-4b75-b39c-9ab42f0ed662"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="D9C330MD8B"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="D9C330MD8B"/>
                <display value="Copovidone"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:3fc6c9e0-da0f-44d6-93b7-16590597f7b6"/>
    <resource>
      <Ingredient>
        <id value="3fc6c9e0-da0f-44d6-93b7-16590597f7b6"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="6W9PS8B71J"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="6W9PS8B71J"/>
                <display value="Sorbitan laurate"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:73445cfe-fcfc-4e6a-9c4a-8ef53cfc5095"/>
    <resource>
      <Ingredient>
        <id value="73445cfe-fcfc-4e6a-9c4a-8ef53cfc5095"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="ETJ7Z6XBU4"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="ETJ7Z6XBU4"/>
                <display value="Silica colloidal anhydrous"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:96ab37c6-19e1-42a1-ba44-b547e736cbad"/>
    <resource>
      <Ingredient>
        <id value="96ab37c6-19e1-42a1-ba44-b547e736cbad"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="L11K75P92J"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="L11K75P92J"/>
                <display value="Calcium hydrogen phosphate anhydrous"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:581adab7-846f-4555-93ba-1d5be1bf740d"/>
    <resource>
      <Ingredient>
        <id value="581adab7-846f-4555-93ba-1d5be1bf740d"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="7CV7WJK4UI"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="7CV7WJK4UI"/>
                <display value="Sodium stearyl fumarate"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:2aeb8dda-b7f6-4156-9328-7cbcbd6d6328"/>
    <resource>
      <Ingredient>
        <id value="2aeb8dda-b7f6-4156-9328-7cbcbd6d6328"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="3NXW29V3WO"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="3NXW29V3WO"/>
                <display value="Hypromellose"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:adb44c23-3430-4563-80dc-7c09163300f2"/>
    <resource>
      <Ingredient>
        <id value="adb44c23-3430-4563-80dc-7c09163300f2"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="15FIX9V2JP"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="15FIX9V2JP"/>
                <display value="Titanium Dioxide"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:e7af6f11-5f61-47c6-ba60-6130776803b9"/>
    <resource>
      <Ingredient>
        <id value="e7af6f11-5f61-47c6-ba60-6130776803b9"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="3WJQ0SDW1A"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="3WJQ0SDW1A"/>
                <display value="Macrogol"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:3e1df278-c76a-4c00-991a-80e399a6ea20"/>
    <resource>
      <Ingredient>
        <id value="3e1df278-c76a-4c00-991a-80e399a6ea20"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="9XZ8H6N6OH"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="9XZ8H6N6OH"/>
                <display value="Hydroxypropyl cellulose"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:cc341cf7-e010-4d71-bda5-06cc7f09974f"/>
    <resource>
      <Ingredient>
        <id value="cc341cf7-e010-4d71-bda5-06cc7f09974f"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="7SEV7J4R1U"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="7SEV7J4R1U"/>
                <display value="Talc"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:92427491-7091-4952-9f73-e2d77ee3aaa2"/>
    <resource>
      <Ingredient>
        <id value="92427491-7091-4952-9f73-e2d77ee3aaa2"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="ETJ7Z6XBU4"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="ETJ7Z6XBU4"/>
                <display value="Silica colloidal anhydrous"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:cc341cf7-e010-4d71-bda5-06cc7f09974f"/>
    <resource>
      <Ingredient>
        <id value="cc341cf7-e010-4d71-bda5-06cc7f09974f"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="6OZP39ZG8H"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:c984b49f-f53d-468f-af0f-6f12ecc678e9"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="6OZP39ZG8H"/>
                <display value="polysorbate 80"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:7f19fe21-8a9b-4ee9-945f-872be96703ff"/>
    <resource>
      <SubstanceDefinition>
        <id value="7f19fe21-8a9b-4ee9-945f-872be96703ff"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
          <value value="7R9A5P7H32"/>
        </identifier>
        <version value="1"/>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
          </coding>
        </status>
        <description value="Pink, oval, debossing of 'PFE' on one side and '3CL' on the other side."/>
        <molecularWeight>
          <type>
            <text value="exact"/>
          </type>
          <amount>
            <value value="499.53"/>
          </amount>
        </molecularWeight>
        <structure>
          <molecularFormula value="C23H32F3N5O4"/>
        </structure>
        <name>
          <name value="Nirmatrelvir"/>
          <type>
            <coding>
              <system value="http://hl7.org/fhir/substance-name-type"/>
              <code value="Scientific"/>
            </coding>
            <text value="Scientific"/>
          </type>
        </name>
      </SubstanceDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:b0846e21-502f-4e34-adbe-f73f6962ac8f"/>
    <resource>
      <SubstanceDefinition>
        <id value="b0846e21-502f-4e34-adbe-f73f6962ac8f"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
          <value value="O3J8G9O825"/>
        </identifier>
        <version value="1"/>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
          </coding>
        </status>
        <description value="White to off white, capsule shaped film coated tablets, debossed with 'H' on one side and 'R9' on other side"/>
        <molecularWeight>
          <type>
            <text value="exact"/>
          </type>
          <amount>
            <value value="720.95"/>
          </amount>
        </molecularWeight>
        <structure>
          <molecularFormula value="C37H48N6O5S2"/>
        </structure>
        <name>
          <name value="Ritonavir"/>
          <type>
            <coding>
              <system value="http://hl7.org/fhir/substance-name-type"/>
              <code value="Scientific"/>
            </coding>
            <text value="Scientific"/>
          </type>
        </name>
      </SubstanceDefinition>
    </resource>
  </entry>
</Bundle>
